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ABSTRACT 
Glioblastoma (GB) is the most aggressive and fatal tumor of the central 
nervous system (CNS). Despite promising results of different therapeutic 
approaches, conventional treatments such as surgery, radiation and 
chemotherapy with Temozolomide (TMZ) are largely palliative. The 
identification of antigens preferentially expressed in GB and involved in its 
malignant phenotype is critical for developing therapeutic strategies.  
Murine and human GB contain a fraction of cancer cells with stem-like 
features (CSC) and it has been proposed that only this population may be 
responsible for glioma recurrence. We previously found that GLAST, a 
membrane protein with relevant action in glutamate trafficking, is highly 
expressed in murine GL261 glioma stem-like cells (GSC). 
In this study, we first investigated the functional consequences of GLAST 
enrichment using an immune-magnetic sorting approach to isolate GLAST+ 
cells from murine GSC. GLAST+ cells were significantly more tumorigenic 
than GLAST- or unsorted cells (p< 0.0006) when injected intracranially, 
showing the highly invasive nature of this subpopulation. GLAST 
expression and its impact on aggressiveness in vivo constituted a 
background of translational relevance. 
To determine whether GLAST peptide-based immunotherapy protects 
against GL261-gliomas, we treated glioma-bearing mice with three 
subcutaneous injections of four GLAST-derived peptides emulsified with 
Montanide™ ISA 51 VG in association with granulocyte macrophage 
colony-stimulating factor (GM-CSF) injections. We found that immunization 
with GLAST peptides efficiently induces specific anti-tumor response in the 
murine GL261-glioma preventing the tumor progression in 40% of 
immunized mice. The immunization induced relevant effects on tumor 
microenvironment by up-regulating IFNγ and TNFα as well as down-
regulating TGFβ1 and β2. GLAST expression significantly decreased in 
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gliomas from immunized mice, as evaluated by histological analysis and 
real-time PCR. Beyond these changes, trafficking of NK cells, CD8+ T cells 
and CD4+ T cells in the spleens and lymph nodes and their homing ability 
into the brain significantly increased in immunized mice when compared 
with controls.  
A local chemotactic gradient characterized by expression of CXCL10 
(which may be responsible for the recruitment of CTL), CCL3, CCL4 and 
CCL5 (which are involved in NK cell migration), and NKG2D ligand in 
immunized mice may play a role in the accumulation of immune cells 
(particularly of NK cells) at the sites of tumor formation. 
Autoimmune reactions were not observed in immunized mice supporting 
evidence that GLAST may constitute a glioma antigen against which 
immune responses can be efficiently induced without toxicity.  
In order to emphasize the translational relevance of GLAST as marker and 
glioma-associated antigen we will extend our studies to human GB.  
GLAST expression was investigated by immunohistochemistry in 39 human 
primary GB. High percentage of GLAST+ cells, and a moderate or strong 
reactivity, was associated with a decreased overall survival (p= 0.02).  
The main result of this study is the definition of GLAST as an attractive 
glioma-associated antigen for targeting in peptide-based immunotherapy in 
GB patients and a potential clinical marker in association with the patient 
prognosis. 
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SOMMARIO 
Il Glioblastoma (GB) è il tumore più aggressivo e fatale del sistema nervoso 
centrale (SNC). Nonostante i promettenti risultati di diversi e nuovi approcci 
terapeutici, i trattamenti convenzionali quali la chirurgia, la radioterapia e la 
chemioterapia con Temozolomide (TMZ), sono ancora oggi palliativi. 
L'identificazione di antigeni preferenzialmente espressi nel GB, e coinvolti 
nel suo fenotipo maligno, è fondamentale per lo sviluppo di strategie 
terapeutiche.  
GB murini e umani contengono una frazione di cellule tumorali con 
caratteristiche simil-staminali (CSC) ed è stato proposto che questa 
sottopopolazione cellulare sia la sola responsabile dell’insorgenza di 
recidive. Nel nostro laboratorio abbiamo scoperto recentemente che 
GLAST, un trasportatore di membrana con un ruolo fondamentale nel 
traffico di glutammato, è altamente espresso in cellule murine GL261 simil-
staminali (GSC). 
In questo studio abbiamo per prima cosa analizzato le conseguenze 
funzionali dell’arricchimento di GLAST in GSC murine, utilizzando una 
tecnica di separazione immunomagnetica che ci ha permesso di isolare 
cellule GLAST+. Quando iniettate intracranialmente le cellule GLAST+ 
hanno mostrato avere una natura altamente tumorigenica rispetto le cellule 
GLAST- o rispetto le cellule non sortate (p< 0.0006), evidenziandone la 
natura altamente invasiva. L’espressione di GLAST e il suo impatto 
sull’aggressività del tumore in vivo hanno costituito la base e un razionale 
di rilevanza traslazionale per questo studio. 
Per determinare se un approccio di immunoterapia a base di peptidi fosse 
in grado di proteggere da tumori derivanti da GL261, abbiamo trattato topi 
con glioma con tre iniezioni sottocutanee di quattro peptidi, derivanti dalla 
sequenza aminoacidica di GLAST; i peptidi sono stati precedentemente 
emulsionati in Montanide™ ISA 51 VG e somministrati in associazione con 
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iniezioni locali di granulocite macophage-colony stimulating factor (GM-
CSF). 
Abbiamo evidenziato che l’immunizzazione con i peptidi di GLAST si è 
rivelata efficace nell’indurre una risposta immunitaria antitumorale 
sistemica e locale specifica, prevenendo la progressione del tumore nel 
40% dei topi trattati. 
L’immunizzazione ha indotto effetti rilevanti sul microambiente tumorale 
attraverso l’up-regolazione di IFNγ e TNFα e, contemporaneamente, la 
down-regolazione di TGFβ1 and β2. 
L'espressione di GLAST, valutata mediante analisi isologica e Real-Time 
PCR, è risultata significativamente diminuita nei gliomi dei topi immunizzati.  
Oltre a queste osservazioni, abbiamo evidenziato che i gliomi dei topi 
immunizzati, rispetto ai topi non trattati, mostrano un aumento di infiltrato di 
cellule natural killer (NK) e di cellule T citotossiche (CD8+) antigene-
specifiche che esprimono la molecola di homing nota come very late 
antigen-4 (VLA-4). 
Un gradiente chemiotattico locale osservato nei topi immunizzati, 
caratterizzato dall’espressione di CXCL10 (che può essere responsabile 
del reclutamento di CTL), CCL3, CCL4 e CCL5 (coinvolti nella migrazione 
delle cellule NK), e del ligando NKG2D, può aver giocato un ruolo 
fondamentale nell'accumulo di cellule immunitarie (in particolare di cellule 
NK) nei siti di formazione del tumore contribuendo ad un aumento della 
sopravvivenza. Molto importante, non sono state osservate reazioni 
autoimmuni nei topi immunizzati, fornendo una prova che GLAST può 
essere sfruttato come antigene contro il quale indurre un’efficace risposta 
immunitaria antitumorale senza tossicità. 
Per sottolineare la rilevanza traslazionale di GLAST come marcatore e 
antigene glioma-associato amplieremo i nostri studi anche su GB umani. 
L’espressione di GLAST è stata studiata in 39 GB primari mediante 
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immunoistochimica. Un’alta percentuale di cellule GLAST+, e una sua forte 
o moderata reattività, può essere associata ad una minore  sopravvivenza 
in pazienti affetti da GB (p= 0.02). 
Il risultato principale di questo studio è stato la definizione di GLAST come 
un attraente antigene glioma-associato, target in un approccio di 
immunoterapia a base di peptidi e potenzialmente sfruttabile anche nel 
trattamento di GB umani. Inoltre abbiamo dimostrato che è possibile 
considerare GLAST come un potenziale marcatore clinico associabile alla 
prognosi del paziente. 
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AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APC: antigen presenting cell 
bFGF: basic fibroblast growth factor 
BSA: bovine serum albumin 
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CTLA-4: cytotoxic T-lymphocyte antigen-4 
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EGF: epidermal growth factor 
EGFR: epidermal growth factor receptor 
EGFRvIII: epidermal growth factor receptor variant III 
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FAK: focal adhesion kinase 
FBS: fetal bovine serum 
FDA: food and drug administration  
GB: glioblastoma multiforme 
GSC: glioma stem-like cell 
GFAP: glial fibrillary acidic protein 
GLAST: glutamate aspartate transporter  
GM-CSF: granulocyte macrophage-colony stimulating factor 
HIF-1α: hypoxia inducible factor-1α  
HLA: human leukocyte antigen  
ICAM-1: intercellular adhesion molecule-1 
IDH1 and IDH2: isocitrate dehydrogenase 1 and 2 
IDO: indoleamine 2,3-dioxygenase 
IFNγ: interferon-γ 
IL-: interleukin-  
LAK: lymphocyte-activated killer cells 
 
	  
2	  
MAGE: melanoma antigen-encoding genes 
MGMT: O-6-methylguanine-DNA methyltransferase 
MHC: major histocompatibility complex 
NK: natural killer 
NMDA: N-methyl-D-aspartic acid  
NOS: nitric oxide synthases 
PCR: polymerase chain reaction 
PDGFR: platelet-derived growth factor receptor 
PGE2: prostaglandin E2 
PTEN: phosphatase and tensin homolog 
SART: squamous cell carcinoma antigen recognized by T cells 
STAT-3: signal transducer and activator of transcription-3 
TAP: transporter associated with antigen processing 
TGFβ: trasforming growth factor-β 
TILs: tumor-infiltrating lymphocyte 
TLR: toll-like receptor 
TNFα: tumor necrosis factor-α 
TRP: tyrosinase-related protein 
VCAM-1: vascular cell adhesion molecule-1  
VEGF: vascular endotelial growth factor 
VEGFR: vascular endotelial growth factor receptor 
VLA-4: very late antigen-4 
WHO: world health organization 
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1.1 Glioblastoma Multiforme 
1.1.1 Introduction 
Glioblastoma (GB) is the most aggressive form of gliomas, central nervous 
system (CNS) malignant tumors. Despite ceaseless efforts by researchers 
and physicians to find new therapeutic strategies, there have been no 
significant advances in the treatment of GB for several decades and most 
patients with GB die within one and half years of diagnosis. However, 
recent information regarding the genetic and epigenetic alterations in GB 
has helped elucidate the formation of this tumor in more detail [1]. 
1.1.2 Classification 
Gliomas are histologically classified as astrocytomas, oligodendrogliomas 
and oligoastrocytomas. They are graded on the World Health Organization 
(WHO) grading system according to their degree of malignancy. The most 
malignant Grade IV gliomas (GB) exhibit advanced features of malignancy, 
which include necrosis, vascular proliferation and pleomorphism [2] [Fig.1]. 
Patients with GB generally die within one and half years from the time of 
diagnosis because of their strong resistance to conventional therapies, 
which include surgery, chemotherapy and irradiation.  
Although until recently chemotherapy for GB did not substantially improve 
disease outcome when combined with other treatment methods. The 
median survival of the patients who received this combination treatment 
was 14.6 months. This is 2.5 months longer than the median survival time 
of patients who received radiation therapy alone. Therefore, combination 
therapy using temozolomide (TMZ) and radiation is now widely used 
worldwide. 
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Fig. 1 Imaging of a 58-year-old female with GB. Contrast-enhanced MR images: (a) axial and (b) saggital 
showing a large enhancing mass in the deep site of the right frontal lobe and involved to midline. Surrounding 
edema and the cerebral compression with midline shift are also evident. The lesion has a mixed signal with 
hyperintense or hypointense signaling on T1-weighted gadolinium-enhanced images. Histopathological 
examination confirmed the diagnosis of GB (Xian Z et al, 2012). 
 
Although numerous genetic alterations have been described in GB [3,4], 
such markers have proven to be of marginal utility in predicting outcome or 
guiding decisions regarding disease management.  
GB have been subdivided into primary or secondary GB subtypes on the 
basis of their clinical presentation. Primary GB are generally found in older 
patients, while secondary GB are found in younger patients. Primary GB 
are not associated with prior symptoms or with evidence of detectable 
antecedent lower grade tumors. In contrast, secondary GB arise from lower 
grade gliomas within 5-10 years of diagnosis [5]. Although they have 
distinctive clinical histories, primary and secondary GB exhibit features that 
are histologically similar and are generally associated with an equally poor 
prognosis [Fig.2].  
Several genes, such as Tumor protein 53 (TP53), p16Ink4a, Phosphatase 
and Tensin Homolog Deleted from Chromosome 10 (PTEN) and Epidermal 
Growth Factor Receptor (EGFR), are altered in both primary and secondary 
GB [6,7].  
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These alterations are thought to occur in a sequential order during the 
malignant progression of gliomas. Loss or mutation of the PTEN tumor 
suppressor gene and amplification or overexpression of the EGFR 
oncogene are thought to be a characteristic of primary GB, whereas 
mutation of the TP53 tumor suppressor gene appears to be an early event 
during the development of secondary GB [8-10]. Most importantly, 
abnormal activation of growth factor signaling and dysregulation of cell 
cycle checkpoints are found in both types of GB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Distinct molecular alterations between primary and secondary GB. GB formation is either de novo 
(primary GB) or due to the progression of a lower grade glioma to a higher grade one through the acquisition of 
additional mutations (secondary GB). The mutations listed are a subset of those found in these tumours that 
have some correlation with glioma grade and GB type. Also listed are some biological effects of these 
mutations and changes in gene expression that might contribute to their roles in gliomagenesis (Holland EC et 
al, 2001).  
 
In a work of 2010, Verhaak proposed a classification of GB based on 
genomics and genetics identifying four distinct classes that are potentially 
responsive to different therapeutic approaches [11]. These subtypes are 
classified as: proneural, classical, mesenchymal and neural. According to 
this study, the proneural subtype is associated with GB that occur at a 
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young age and with secondary GB characterized by p53 and IDH1 
mutations. This group of GB express oligodendroglial markers. Instead, the 
classic subtype presents chromosome 7 amplification, chromosome 10 
deletion and amplification of epidermal growth factor receptor (EGFR). 
Mesenchymal GB show high expression of mesenchymal markers and a 
enhanced invasive capacity. Finally, the neural subtype is associated with 
neural markers.  
The classification of GB into several subtypes, however, is at the canter of 
several debates and remains to be clarified. Phillips et al, for example, due 
to genetic characterizations carried out on different human GB lines 
analysis, divides GB in three classes: the proneural, the proliferative and 
mesenchymal subtype [12]. The proliferative subtype, or classic, had been 
proposed previously [13] and it was confirmed in this study by classifying 
those lines that exhibit a high proliferation mainly due to amplification of 
EGFR and PDGFR. In this study, the mesenchymal and the proneural 
subtypes coincide, in part, with the characteristics identified by Verhaak in 
the same molecular subtypes. 
 
1.1.2.1 Activated growth factor signaling pathways 
Various growth factors, such as platelet-derived growth factor (PDGF)-A, 
PDGF-B, epidermal growth factor (EGF), transforming growth factor (TGF)-
β, insulin growth factor (IGF)-1 and fibroblast growth factor (FGF) are often 
produced and secreted in GB. In addition, the various growth factor 
receptors corresponding to each specific growth factor are often 
overexpressed in GB. Consequently, the autocrine/paracrine loops 
between ligand and receptor enhance their impact in gliomagenesis 
[14,16]. Several important signaling pathways, such as Ras-mitogen-
activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)-AKT 
and Phospholipase-C gamma (PLCγ)-Protein Kinase C (PKC) are activated 
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downstream of growth factor receptors. Recent reports using genetically 
engineered mice suggest that these growth factor signaling cause the 
formation of gliomas directly [17]. 
 
1.1.2.2 Dysregulation of cell cycle checkpoints 
The eukaryotic cell cycle is composed of four distinct phases: G1 phase, S 
phase (DNA synthesis), G2 phase and M phase (mitosis). Through the cell 
cycle, the genetic materials are correctly replicated and transmitted to the 
two daughter cells. Accurate regulation of the cell cycle is crucial for the 
survival of cells. Each phase has to progress in a sequential fashion and, to 
activate each phase, proper progression and completion of the previous 
phase is required. The engine of the cell cycle is the cyclin-cyclin-
dependent kinase (CDK) complex. Cyclins constitute the regulatory subunit 
and CDK is the catalytic subunit of an activated heterodimeric kinase 
complex.  
When cells receive promitotic extracellular signals, G1 cyclin-CDK 
complexes are activated and promote the expression of transcription 
factors, which leads to the increase of S-phase cyclin expression. The 
disruption of cell cycle checkpoints caused by the dysregulation of major 
tumor suppressors appears to be crucial for gliomagenesis. Firstly, the 
TP53 gene is either mutated or deleted in certain gliomas, particularly in 
secondary GB. Secondly, the retinoblastoma (RB) gene is mutated in 10-
25% of high-grade astrocytomas.  
In addition, RB is functionally silenced in another 15% of astrocytomas via 
the amplification of its antagonist CDK4. Lastly, the CDKN2A locus 
encoding p16INK4A and p14Arf (which positively regulate the RB and TP53 
pathways, respectively) is deleted in approximately half of high-grade 
astrocytomas [18-19]. 
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1.1.2.3 Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutation in GB 
Recently, a somatic mutation at amino acid 132 of the isocitrate 
dehydrogenase 1 (IDH1) protein was identified in more than 70% of WHO 
Grade II and III astrocytomas, oligodendrogliomas and secondary GB [20]. 
Surprisingly, tumors expressing an intact IDH1 gene often have mutations 
at the analogous amino acid 172 of the IDH2 protein. 
A recent report showed that forced expression of a mutated IDH1 gene in 
cultured cells results in the reduction of the enzyme product α-ketoglutarate 
(α-KG), which leads to the increase of the levels of the hypoxia-induced 
factor-1α (HIF-1α), the stability of which is regulated by α-KG. Because 
HIF-1α is thought to promote tumor growth at low oxygen levels, mutation 
of the IDH1 gene may facilitate tumor progression in GB. It should be noted 
that mutations in the IDH1 or IDH2 genes are identified in the vast majority 
of WHO Grade II or III gliomas and secondary GB [21]. 
 
1.1.2.4 Aberrant function of MicroRNA in GB 
It has been speculated that at least one-third of all protein-coding genes in 
the human genome are partially regulated by microRNAs [22] MicroRNAs, 
which are single-stranded RNA molecules that comprise approximately 20-
22 nucleotides, have been shown to play a central role in biological 
processes and distinct patterns of microRNA expression are seen in 
different normal cells and tissues [23]. MicroRNAs are noncoding RNAs 
from various chromosomal origins, which include intergenic, intronic, or 
exonic regions. The primary transcripts of microRNAs (Pri-miR) are 
transcribed from the genome by RNA polymerase II and are processed 
through a conserved mechanism to yield mature microRNAs. Mature 
microRNAs recognize partially complementary sequences in the 3’-UTR of 
their target genes and decrease the mRNA levels of the target by cleavage 
or by inhibiting translation initiation directly [24]. 
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Many reports on the functions of microRNAs suggest that microRNAs have 
hundreds of potential targets and regulate multiple signaling pathways. 
Various levels of microRNA expression have been observed in cancers, 
including GB [25]. For example it has been reported that microRNA-21 
(miR-21) is highly expressed in GB [26]. Inhibition of miR-21 in glioma cell 
lines results in the increase of caspase-dependent apoptosis, which 
suggests that miR-21 acts as an oncogene by inhibiting apoptosis. MiR-7 is 
down-regulated in GB and targets EGFR [27]. MiR-7 has also been 
reported to target insulin receptor substrate-2 (IRS-2), which is an adaptor 
protein that mediates PI3K signaling downstream of receptor tyrosine 
kinases and suppresses AKT activation. 
In a recent publication of my group [28], Speranza M et al focused on 
NEED9, a novel target of mir-145. mir-145 is an important repressor of 
pluripotency in embryonic stem cells and a tumor suppressor in different 
cancer. We found that mir-145 is strongly down-regulated in GB specimens 
and corresponding glioblastoma-neurospheres (GB-NS, containing GB 
stem-like cells) compared to normal brain and low-grade gliomas (LGG). 
We focused the attention on HEF1/CasL/NEDD9, a scaffold protein 
involved in invasion in several types of cancer. We confirmed a significant 
down-regulation of NEDD9 in miRover-NS and a higher expression in GB 
compared to normal brain. We observed that intracranial injection of GB-NS 
over-expressing mir145 delays significantly tumor development: deriving 
tumors showed a significant down-regulation of NEDD9. Our results 
demonstrate the critical role of mir-145 and NEDD9 in regulating 
glioblastoma invasion and suggest a potential role of NEDD9 as a 
biomarker for glioma progression [28]. 
 
 
1.2 Medical treatment & management of glioblastoma 
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1.2.1 Introduction 
Until relatively recently the treatment of GB with chemotherapeutic agents 
remained controversial due to lack of proven efficacy. Standard therapy for 
newly diagnosed GB consisted of maximum safe resection followed by 
fractionated external-beam radiotherapy [29]. Chemotherapy was often 
given concurrently with radiation or as an adjuvant, at time of initial 
diagnosis but after the completion of surgery and radiation, but its use was 
inconsistent and geographically variable. This began to change in the late 
1980s with the investigation of temozolomide (TMZ), an orally administered 
alkylating agent. In 2005, a large Phase III trial of TMZ given concurrently 
with radiation therapy and as an adjuvant after radiation for newly 
diagnosed GB showed a significant survival benefit over radiation alone [1]. 
This regimen has since become the standard of care for patients with newly 
diagnosed GB. Further trials are ongoing to investigate the relative 
contributions of concurrent and adjuvant TMZ in treating GB and a variety 
of alternative TMZ administration. 
Another recent approach to GB therapy is the use of molecularly targeted 
agents-low molecular weight kinase inhibitors and monoclonal antibodies 
that act as specific inhibitors of the signaling pathways implicated in tumor 
growth and survival. Angiogenesis has long been recognized as a key 
player in tumor growth and vascular proliferation is a defining feature of GB, 
so it is little surprise that therapies targeting the vascular endothelial growth 
factor (VEGF) system have been met with great enthusiasm in the neuro-
oncology community. A wide variety of other signaling pathway agents are 
being evaluated both as monotherapies and in combination with traditional 
alkylating chemotherapy or alongside other targeted agents.  
 
1.2.2 Cytotoxic chemotherapy for GB 
1.2.2.1 Temozolomide 
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Temozolomide (TMZ) is an orally administered methylating agent with 
excellent bioavailability and blood-brain barrier penetration [1]. TMZ is a 
prodrug which is metabolized into 3-methyl-(triazen-1-yl)imidazole-4-
carboxamide (MTIC). MTIC methylates DNA at a number of sites, most 
frequently N7-guanine and N3-adenine. While the conversion of O6-
guanine to 06-methylguanine is less frequent, accounting for only about 5% 
of all methylation events, it induces a futile cycle of DNA mismatch repair 
which leads to double-stranded breaks and cellular apoptosis, thus serving 
as the primary mediator of TMZ-mediated cytotoxicity [30].  
Temozolomide was first evaluated in glioma as a treatment of recurrent 
malignant glioma following radiation therapy, where it was shown to have 
good antitumor activity as a monotherapy and an acceptable side effect 
profile. Following the success of this approach, TMZ was evaluated in 
combination with radiation therapy as a treatment for newly diagnosed GB 
[31].  
There are several mechanisms of tumor resistance to TMZ; the two with 
greatest implications for GB therapy are the O6-methylguanine DNA 
methyltransferase (MGMT) and poly(ADP-ribose) polymerase (PARP) 
systems. Methylation of O6-guanine, which as previously mentioned is the 
primary mediator of TMZ cytotoxicity, is repaired by the enzyme MGMT. 
MGMT is irreversibly inactivated in the process and de novo synthesis is 
required to maintain enzyme activity [32]. While MGMT is widely expressed 
in both normal human tissue and neoplasms, MGMT protein expression is 
heterogeneous within tumors due to frequent epigenetic silencing via gene 
promoter hypermethylation [33] As would be predicted from its mechanism, 
the level of MGMT protein within tumor tissue correlates with response to 
TMZ and MGMT promoter methylation predicts increased survival in 
patients with malignant glioma.  
The irreversible inactivation of MGMT during DNA repair provides an a 
priori basis for the potential utility of dose-dense TMZ regimens by 
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suggesting that it may be possible to effectively overcome this 
chemotherapy resistance mechanism by designing a regimen in which 
increased or prolonged TMZ exposure leads to depletion of MGMT. MGMT 
can also be inhibited directly by O6-benzylguanine (O6-BG) and related 
agents and a number of recent studies have examined the combination of 
TMZ and MGMT inhibitors [34, 35].  
 
1.2.2.2 Non-temozolomide systemic chemotherapy 
Prior to the introduction of TMZ, the use of adjuvant chemotherapy along 
with surgery and radiation was inconsistent and geographically variable. 
When adjuvant therapy was employed, nitrosourea class compounds such 
as carmustine (BCNU) or lomustine (CCNU) were commonly chosen for 
their ability to cross the blood-brain barrier. CCNU was often combined with 
procarbazine, a DNA alkylating agent and vincristine, which disrupts 
microtubule formation, to create the regimen known as PCV. Despite 
decades of evaluation, no nitrosourea-based adjuvant treatment was 
unambiguously shown to confer a survival benefit beyond that achieved by 
radiation therapy alone in a Phase 3 randomized controlled trial. Several 
meta-analyses of have examined the available RCT data, the most rigorous 
of which showed a small but significant survival benefit equivalent to a 6% 
absolute increase in 1-year survival [36].  
While TMZ has now supplanted the nitrosoureas as the adjuvant agent of 
choice as a monotherapy, combination therapies such as TMZ/ CCNU are 
being investigated which may offer survival benefits superior to TMZ alone 
[37]. Carboplatin is a platinum-based compound that interferes with DNA 
replication by producing cross-links within DNA strands. Intravenous 
carboplatin has modest activity against recurrent malignant glioma both in 
chemotherapy naive patients 31 Low-dose carboplatin has been shown to 
act as a radiosensitizer in some non-CNS solid tumors, but the addition of 
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carboplatin to radiation therapy for newly diagnosed malignant glioma did 
not increase survival time [38]. 
 
1.2.2.3 Surgically implanted carmustine (BCNU) coated wafers (Gliadel) 
The relatively minimal antitumor activity of systemically administered 
nitrosourea-based chemotherapy has led to a variety of alternative 
approaches to chemotherapy delivery. The most studied method is the 
implantation of BCNU impregnated wafers (Gliadel) into the tumor cavity at 
the time of resection. These wafers then provide a controlled release of 
BCNU over a period of 2 to 3 weeks. This approach has several theoretical 
advantages over systemic chemotherapy, including the ability to deliver a 
greater dose to residual tumor and a more benign systemic side effect 
profile. A recent meta-analysis of the use of Gliadel for high grade glioma 
concluded that the addition of Gliadel to radiotherapy led to increased 
survival relative to radiotherapy alone for newly diagnosed tumors, but that 
there was no significant increase in survival with Gliadel therapy for 
recurrent disease [39]. 
 
1.2.3 Molecular-targeted therapies for GB 
1.2.3.1 Angiogenesis pathways and agents: Vascular Endothelial Growth 
Factor (VEGF) 
The role of angiogenesis in tumor survival and growth has been recognized 
since the early 1970s [40]. Tumors utilize many different mechanisms to 
produce their blood supply. The prototypical example is the vascular 
endothelial growth factor (VEGF) system. Gliomas, along with most other 
human solid tumors, express VEGF at elevated levels. VEGF expression is 
triggered by a number of factors, notably hypoxia and acidosis, which are 
commonly seen in high-grade tumors. VEGF then acts on endothelial cells 
to trigger increased vessel formation [41]. 
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The first targeted anti-angiogenic agent shown to have efficacy against 
malignant glioma was bevacizumab (Avastin®), a monoclonal antibody 
against VEGF. Prior to its use in glioma, bevacizumab was shown to 
improve outcome in non-CNS malignancies such as colon cancer when 
given with cytotoxic chemotherapy [42], where it is thought to lead to 
improved chemotherapy response by allowing normalization of blood 
vessels. Given this background, initial trials of bevacizumab for GB patients 
combined the therapy with irinotecan, a conventional chemotherapeutic 
agent. Many studies of bevacizumab including combination therapy trials 
with other targeted agents are ongoing. 
While bevacizumab is the best-studied of the VEGF pathway modifiers, 
several other agents are currently being evaluated. Aflibercept (VEGF 
Trap) is a soluble receptor that binds circulating VEGF and placental 
growth factor (PlGF), a related ligand of the VEGFR.  
Small molecule kinase inhibitors aimed at VEGFR include vatalanib, 
pazopanib, cediranib and CT-322. While none of these therapies has 
shown unequivocal survival benefit in patients with glioma, cediranib 
therapy does lead to a rapid and dramatic radiographic response due to 
reversible vascular normalization [43]. In addition to the VEGF-specific 
therapies above, several agents currently under investigation act on VEGF 
in addition to other targets of glioma growth. Examples include sunutinib, 
vandetanib, sorafinib and axitinib. Anti-VEGF therapy is generally well 
tolerated.  
 
1.2.4 Drug resistance in GB 
Drug resistance in GB is one of the major factors that render this type of 
tumor incurable. EGFR is frequently amplified, overexpressed, or mutated 
in GB [9]. An activated form of EGFR mutant caused by the deletion of 
exons 2-7 (known as EGFRvIII) occurs in 20-30% of GB; EGFRvIII reduces 
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apoptosis and increases the proliferation of GB cells [44]. In addition, 
EGFRvIII has the capacity to malignantly transform murine Ink4a/Arf null 
neural stem cells (NSC) or astrocytes [45]. 
Therefore, EGFR is a strongly validated molecular target for GB treatment 
and the use of EGFR inhibitors is a reasonable therapeutic strategy for this 
disease. However, only 10-20% of GB patients respond to EGFR inhibitors. 
Although the mechanism of the resistance of GB to EGFR inhibitors is not 
known, the loss of PTEN is suggested to be associated with this 
mechanism. PTEN is commonly lost in GB and is an inhibitor of the PI3K 
signaling pathway, which is activated downstream of EGFR. It is suggested 
that loss of PTEN may dissociate EGFR inhibition from the PI3K pathway 
inhibition, which may result in the resistance of GB to EGFR inhibitors [46]. 
 
1.3 Cancer stem cells hypothesis 
1.3.1 Introduction 
The cancer stem cells (CSC) hypothesis has provided an alternative 
framework for understanding cancer heterogeneity, tumorigenesis and 
cancer progression. Recent identification of cancer-initiating stem cells in 
brain tumor [47, 48] and in other types of cancer suggested that CSC may 
play a central role in the propagation of several cancer types. CSC have 
also been shown to be responsible for prevalent radio-resistance and 
chemo-resistance in glioma [49].  
Compared to conventionally cultured human cancer cell lines, CSC have 
been shown to recapitulate human brain tumors in phenotype and in cancer 
genetics and thus may more faithfully model mechanisms of tumorigenesis 
and tumor propagation. 
The identification of glioma stem cells may have important applications in 
cancer therapy for glioma patients. Therapies targeting glioma stem cells 
may help overcome the persistent cancer resistance to chemotherapies 
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and radiation therapies. In addition, strategies targeting glioma stem cells 
may have positive impact on the development of immunotherapy for 
malignant brain cancer patients. Different hypothesis on the origin of CSC 
were postulated. They may be described as follow: 
- Cancer cells arise from stem cells. Stem cells are distinguished from other 
cells by two characteristics: (1) they can divide to produce copies of 
themselves, or self-renew, under appropriate conditions and (2) they are 
pluripotent, or able to differentiate into most, if not all, mature cell types. If 
CSC arise from normal stem cells present in the adult tissue, de-
differentiation would not be necessary for tumor formation. In this scenario, 
cancer cells could simply utilize the existing stem-cell regulatory pathways 
to promote their self-renewal. The ability to self-renew gives stem cells long 
lifespans relative to those of mature differentiated cells. It has therefore 
been hypothesized that the limited lifespan of a mature cell makes it less 
likely to live long enough to undergo the multiple mutations necessary for 
tumor formation and metastasis. 
- The differentiation pathway from a stem cell to a differentiated cell usually 
involves one or more intermediate cell types. These intermediate cells, 
which are more abundant in adult tissue than are stem cells, are called 
progenitor or precursor cells. They are partly differentiated cells present in 
fetal and adult tissues that usually divide to produce mature cells. However, 
they retain a partial capacity for self-renewal. This property, when 
considered with their abundance relative to stem cells in adult tissue, has 
led some researchers to postulate that progenitor cells could be a source of 
CSC. 
- Some researchers have suggested that cancer cells could arise from 
mature, differentiated cells that somehow de-differentiate to become more 
stem cell like. In this scenario, the requisite oncogenic (cancer causing) 
genetic mutations would need to drive the de-differentiation process as well 
as the subsequent self-renewal of the proliferating cells. This model leaves 
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open the possibility that a relatively large population of cells in the tissue 
could have tumorigenic potential; a small subset of these would actually 
initiate the tumor. Specific mechanisms to select which cells would be 
differentiated have not been proposed. However, if a tissue contains a 
sufficient population of differentiated cells, the laws of probability indicate 
that a small portion of them could, in principle, undergo the sequence of 
events necessary for de-differentiation. Moreover, this sequence may 
contain surprisingly few steps; researchers have recently demonstrated that 
human adult somatic cells can be genetically "re-programmed" into 
pluripotent human stem cells by applying only four stem-cell factors. These 
three hypotheses are summarized in [Fig.3]. 
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Fig. 3 Schematic representation of the possible relationships between neural stem cells (NSC), neural 
progenitors, CSC and brain tumours. (a) CSC originate from NSC or progenitor cells upon acquisition of 
genetic mutations and give rise to brain tumours, the maintenance of which is mediated by CSC. (b) Progenitor 
cells or even differentiated cells are the cell of origin of a brain tumour after occurrence of genetic mutations. 
Tumour stem cells found in brain tumours are a by product of tumorigenesis, required for tumour maintenance 
but not for tumour initiation. (a, b) Dotted arrows indicate possible de-differentiation of cells as an alternative 
cell of origin of tumours. Grey semi-circles signify self-renewal capacity of NSC and CSC (Sutter R et al, 2007). 
 
1.3.2 Glioma stem cells as cancer initiating cells 
GB can be initiated from brain tumor stem-like cells (BTSC) [48]. However, 
unlike normal tissue stem cells, CSC may be heterogeneous, meaning that 
all CSC from tumors of the same tissue origin and grade, or even from the 
same tumor, are not the same [50]. For example, both CD44+/CD24- and 
CD133+ cell populations had been identified from the same cancer in a 
BRCA breast cancer model, suggesting that one initial mechanism may 
lead to diverse CSC with different phenotypes [51]. 
The capability of BTSC to sustain brain tumor growth apparently lies in their 
active self-renewal and/or suppressed cell differentiation. Several major 
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signaling pathways that are critical in brain development have also been 
implicated in tumorigenesis, including: bone morphogenetic protein (BMP) 
[52] Notch [12] and Sonic Hedgehog (SHH) [53] EGFR [54] 
PTEN/PI3K/Mtor [55] PDGFR [56] and OLIG2 [57]. 
Recently, a gene expression profiling of gliomas has shown that SHH 
signaling is active in a subset of gliomas. This study further showed that 
SHH signaling is essential for glioma CSC self-renewal and CSC-initiated 
brain tumor growth. It is postulated that the relative homogenous population 
of CSC, rather than the heterogeneous tumor cells, may reveal key 
mechanisms of tumor initiation and propagation of primary tumors and 
hence predict clinical prognosis, therapy and drug response of tumors.  
The identification of both SHH signaling-dependent and independent brain 
tumors in this study suggested that there are molecularly distinct 
subclasses of GB that have an effect on progression and prognosis. These 
findings were reminiscent of a recent study in which high-grade gliomas 
were classified into a proneural subclass and a mesenchymal subclass, 
resembling two stages in neurogenesis [12]. In that study, Phillips et al 
discovered a prognostic model utilizing PTEN-AKT and Notch signatures to 
predict poor versus better glioma prognosis, respectively. 
In an other study, the SHH signaling-dependent brain tumors showed high 
activities in Notch and PDGFR pathways, while the SHH signaling-
independent brain tumors showed PTEN-deficiency and high activity in 
PI3K-AKT pathway. In this study authors also described that brain tumor 
stem cells, with distinct signaling patterns, determined the different GB 
phenotypes and progression [58]. 
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1.4 Basic concepts in glioma immunology 
1.4.1 Introduction 
Despite aggressive treatment with surgery, radiation and chemotherapy, 
average survival for glioblastoma patients remains only 14 months. More 
effective therapies are urgently needed. Immunotherapy (stimulating the 
immune system to attack the tumor) is one such promising therapy. 
Effective immunotherapy requires an understanding of the basic 
immunobiology of these tumors. 
 
1.4.2 Basic concepts in immunology 
The immune system made up of the various cellular and visceral 
components involved in recognizing and eliminating foreign and/or 
dangerous antigens. Anatomically, it is made up of primary and secondary 
lymphoid organs. Functionally, it consists of both innate and adaptive 
immune responses. Innate immunity deals with antigen-nonspecific 
responses to foreign or dangerous molecules. Some of this is 
accomplished at a purely molecular level with the complement system and 
systemic responses to inflammatory cytokines. At a cellular level, it is made 
up of macrophages, neutrophils and natural killer cells.  
Activation of innate immunity is not antigen-specific but is induced in 
response to molecular factors common to multiple infectious or dangerous 
agents. In contrast to innate immunity, adaptive immune responses are 
antigen-specific. Foreign and/or dangerous antigens are scavenged from 
the environment, processed and presented by professional antigen 
presenting cells (APC) of the reticulo endothelial system, including dendritic 
cells and macrophages. APC form an important connection between 
adaptive and innate immunity. Adaptive immunity is comprised of humoral 
(antibody) mediated by B cells and cellular immune responses mediated by 
cytotoxic T cells. Both forms of adaptive immunity require signals from 
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helper T cells. Antigens are presented to T cells in the context of major 
histocompatibility complexes (MHC). Class I MHC are key for presentation 
to CD8+ cytotoxic T cells while class II MHC are important for presentation 
to CD4+ helper T cells. In addition to antigen presentation in the context of 
a MHC molecule, T-cell activation also requires a second costimulatory 
signal most commonly through the T-cell costimulatory molecules B7-1 or 
B7-2 on APC binding their ligand CD28 on T cells [59, 60] [Fig. 4].  
 
 
Fig. 4 Immunological synapse. Target recognition by T cells is two-step process. Specific interaction of T-cell 
receptor (TCR) with major histocompatibility complex (MHC) –peptide complexes displayed by tumor cells or 
antigen-presenting cells (APCs; eg, dendritic cells) provides first signal for T-cell recognition. Second event is 
coregulatory signal that determines whether T cell will become activated or anergic (nonreactive). T-cell 
coreceptors transmitting stimulatory (+) or inhibitory (+) signals on engagement of specific ligands expressed 
by tumor cells or APCs are depicted. Molecules in B7-CD28 and tumor necrosis factor receptor (TNFR) 
families are now being targeted for cancer immunotherapy. 4-1BBL, 4-1BB ligand; BTLA, B- and T-lymphocyte 
attenuator; CTLA-4, cytotoxic T-lymphocyte antigen 4; ICOS, inducible T-cell costimulator; LIGHT, homologous 
to lymphotoxin, shows inducible expression, competes with herpes simplex virus glycoprotein D, expressed by 
T cells; PD-1, programmed cell death 1 (Topalin SL, 2011). 
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1.4.3 Immunology in the CNS 
The brain has long been considered an immunologically privileged site 
owing to its apparent inability to reject intracranial xenografts in older 
report, separation via the blood brain barrier and lack of obvious 
connections with the lymphatic system. However, unlike other 
immunologically privileged site like testes, no specific CNS-associated 
antigens have been described that are immunogenic systemically but 
evade immune detection within the brain. Furthermore, it is now clear that 
the blood brain barrier is only a relative barrier to lymphocyte tracking, 
particularly in pathological states. Connections between cerebrospinal fluid 
and cervical lymphatics have been documented [61, 62]. Abundant 
evidence demonstrates that intracranial xenografts are actually rejected 
very efficiently in all but the most immunocompromised hosts. Microglia, 
resident antigen presenting cells of the central nervous system, play an 
active part in very dynamic immune responses in the brain [63]. Multiple 
pathological states, ranging from multiple sclerosis to Alzheimer’s disease 
to Parkinson’s disease, bear witness to the ability of immune responses to 
occur within the brain. In short, it is clear that, while the central nervous 
system may be an immunologically distinct environment, it is not truly 
immunologically privileged. 
 
1.4.4 Glioblastoma-associated antigens 
A key assumption underlying most attempts at tumor immunotherapy 
(particularly strategies aimed at stimulating adaptive immune responses) is 
that tumors express specific abnormal antigens that can be recognized and 
eliminated by the immune system. Several lines of evidence support this 
assumption in cancer in general and glioblastomas in particular that can be 
demonstrated by discussion of a representative antigen.  
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In glioblastomas, mutant epidermal growth factor receptor-vIII is an 
excellent example of a tumor-specific antigen [64]. EGFRvIII is a truncated 
version of the epidermal growth factor receptor (EGFR) present in 
approximately 30% of glioblastomas. It has lost its extracellular domain and 
is constitutively active. It contains specific peptide sequences that have not 
been described in any normal human tissues and have been used to target 
vaccines [65]. Almost any tumor peptide has potential to function as a 
tumor antigen, leading to a bewildering number of potential targets. This 
begs the question: which antigens are the most attractive targets for 
immunotherapy? The National Cancer Institute of the United States has 
recently attempted to address this issue. They performed an in-depth 
review of 75 tumor-associated antigens that could be targeted by 
immunotherapy [66]. Antigens were ranked based on nine factors: 
therapeutic function, immunogenicity, role in oncogenicity, specificity, 
express level in tumors, cancer stem cell expression, percentage of 
patients with positive tumors and cellular location of expression. The 
highest ranked antigens included WT1, MUC1, LMP2, HPV E6/E7, 
HER2/Neu, EGFRvIII, MAGE A3 and NY-ESO-1. While the expression of 
some of these antigens (e.g., EGFRvIII) by glioblastomas is well 
established, the presence or absence of others (e.g., MUC1) have not been 
reported at all. Only a handful of systematic studies have been performed 
examining expression of potentially immunogenic antigens in glioblastomas 
have been performed. Many have included antigens that did not make the 
NCI’s “top ten” (e.g., gp100, MART) or that were not considered in the NCI 
analysis at all (e.g., IL13Rα) [67]. For the development of new therapies 
against gliomas, it is required to identify tumor antigens as targets for 
specific immunotherapy. 
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Category of Antigens Antigen 
Cancer-testis (CT) 
antigens MAGE1, SOX6 
Tissue-specific antigens Gp100, TRP-2 
Mutated antigens EGFRvIII 
Others 
IL13Ra2, EphA2, EphB6, AIM-2, HER-2, 
WT1, ARF4L, SART-3, SOX11, KIF1C, 
KIF3 
 
Tab. 1. Human glioma antigens recognized by CTL 
 
1.5 Mechanisms of glioma-mediated immunosuppression 
1.5.1 Introduction 
A major contributing factor to glioma development and progression is its 
ability to evade the immune system. Here I would like to explore the 
mechanisms utilized by glioma to mediate immunosuppression and 
immune evasion. These include intrinsic mechanisms linked to its location 
within the brain and interactions between glioma cells and immune cells. 
Lack of recruitment of naïve effector immune cells perhaps accounts for 
most of the immune suppression mediated by these tumor cells. This is 
enhanced by increased recruitment of microglia, which resemble immature 
antigen presenting cells that are unable to support T-cell mediated 
immunity. Furthermore, secreted factors like TGFβ, COX-2 and IL-10, 
altered costimulatory molecules and inhibition of STAT-3 all contribute to 
the recruitment and expansion of regulatory T cells, which further modulate 
the immunosuppressive environment of glioma.  
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1.5.2 Intrinsic mechanism of immunosuppression 
1.5.2.1 Altered human leukocyte antigen expression 
Human leukocyte antigens (HLA) are the MHC molecules in humans.  The 
class I antigens are comprised of three major (classical) genes- HLA-A, -B 
and -C; and three minor (non-classical) genes- HLA-E, -F and -G. The 
classical HLA class I molecules present intracellular antigenic peptides on 
the surface of altered cells, thus targeting the cells for lysis by cytotoxic 
CD8+ T cells (CTL). They are typically expressed by most nucleated cells 
in the body. Analysis of HLA class I antigens expression in 47 GB lesions 
revealed that expression was lost in approximately 50% of the samples 
[68]. The selective loss of HLA class I antigens would suggest a defect in 
antigen presentation by glioma cells and a concomitant impairment of CTL 
lysis. Recently, HLA-G, a non-classical HLA class I molecule, has been 
identified in malignant tumors and glioma cell lines and may be involved in 
tumor immune escape [69]. Another inhibitory molecule is the non-classical 
MHC class I molecule HLA-E. It is the only known ligand for CD94/NKG2A, 
an inhibitory receptor, expressed on NK cells and CD8+ T cells. The over-
expression of HLA-E by glioma cells would render them resistant to NK cell 
and CTL cytotoxicity. Analysis of human long-term glioma cell lines, primary 
ex vivo polyclonal glioblastoma cell cultures and surgical glioblastoma 
specimens, revealed high expression of HLA-E [70]. 
 
1.5.2.2 The role of microglia 
Microglia are the brain’s resident macrophages. They differentiate from 
monocytes which migrate into the brain during embryogenesis. Microglia 
are distinguished from macrophages based on low expression of CD45 and 
high expression of CD11b (CD45dim CD11b+). Under normal physiological 
conditions, microglia roam the CNS, phagocytosing debris and maintaining 
homeostasis. It is likely that microglia may play dual roles during glioma 
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development through the expression of cytokines. Microglia have been 
postulated to support glioma cell proliferation through the production of IL-
10 and IL-6 [71, 72]. IL-10 is also an immunosuppressive cytokine, which 
inhibits T-cell proliferation. Furthermore, microglia express a clearly Th2 
skewed cytokine profile, which suppresses cytotoxic responses. Taken 
together, glioma infiltrating microglia support glioma tumorigenesis while 
promoting immune evasion. 
 
1.5.3 Impairment of glioma and immune cell interactions 
Cell-to-cell contact is required for lymphocytes to lyse tumor cells. 
Specifically, the release of the cytotoxic molecules, perforin and granzyme, 
by natural killer (NK) cells and CTL is cell contact dependent. Glioma cells 
have been shown to alter the extracellular matrix and this may have an 
impact on cell-to-cell contact. Recently, tenascin-C expression has been 
described in glioma cells. Tenascin-C belongs to a specialized class of 
ECM proteins, matricellular proteins, which function as adaptors and 
modulators of cell-matrix interactions [73]. The exact role of tenascin-C is 
unresolved, as it has been implicated in both cell adhesion and migration. 
Tenascin-C has also been shown to inhibit T-cell proliferation and IFNγ-
production. The infiltration of lymphocytes into tumors was inhibited by 
tenascin-C [74]. Through the expression of tenascin-C, glioma cells could 
potentially enhance cell migration, while suppressing T-cell responses by 
limiting cell-to-cell contact. 
 
1.5.4 Glioblastoma-derived immunosuppressive factors 
1.5.4.1 TGF-β 
It has long been recognized that GB secrete multiple immunosuppressive 
factors. Expression of transforming growth factor-β2 (TGFβ2; originally 
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described as glioblastoma-derived immunoinhibitory factor) by glioblastoma 
cells were originally described more than two decades ago [75]. More 
recently, TGFβ1 and -β2 have been shown to induce FoxP3 expression in 
anti-CD3 activated CD4+T cells, resulting in inducible regulatory T cells 
(Treg). Thus, the secretion of TGFβ by glioma cells mediates 
immunosuppression not only by acting directly on T cells and NK cells, but 
also indirectly through the induction of Treg. 
 
1.5.4.2 Cyclooxygenase-2 and Prostaglandin E2 
Cyclooxygenase-2 (COX-2) is an isoform of the cyclooxygenase enzyme or 
prostaglandin synthase responsible for the formation of important biological 
mediators called prostanoids (including prostaglandins, prostacyclin and 
thromboxane). COX-2 is an inducible enzyme, becoming abundant in 
activated macrophages and other cells at sites of inflammation. Inhibitors of 
COX-2 are used as nonsteroidal anti-inflammatory drugs (NSAID) for 
treating inflammation and pain. The over-expression of cyclooxygenase-2 
(COX-2), the key enzyme for the synthesis of prostaglandin E2 (PGE2) 
from arachidonic acid, has also been well characterized in many types of 
cancers including colorectal, lung, urinary bladder and malignant gliomas 
[76]. PGE2, contributes to cellular immune suppression in cancer patients 
through an unknown mechanism. PGE2 is also a potent inducer of IL-10, 
which is produced by a variety of cells including monocytes, and exerts 
suppressive effects on dendritic cell maturation and Th1 responses [77]. 
PGE2 levels were significantly higher in patient glioma samples compared 
to control brain samples [78]. Furthermore, surgical removal of malignant 
brain tumors resulted in a decrease of PGE2 levels. PGE2 has been linked 
to tumor metastasis and immune evasion, such that the inhibition of PGE2 
synthesis using COX inhibitors suppressed tumor growth [79]. 
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1.5.4.3 IL-6 and VEGF 
In addition to these frankly immunosuppressive factors, glioblastomas 
secrete several factors that are profoundly immunomodulatory. Some, such 
as interleukin-6 (IL-6) and colony stimulating factor-1 (CSF-1) have obvious 
immune functions such as shifting adaptive immunity to humoral (TH2) 
responses that may be less effective against solid tumors and/or attracting 
and stimulating monocytic cells [80]. Others, such as vascular endothelial 
growth factor (VEGF), impact immune responses in a more tangential 
fashion. Tumor-derived VEGF acts primarily as a pro-angiogenic factor and 
can be targeted for anti-angiogenic therapy (e.g., bevacizumab). 
 
1.5.5 Induction of T cell anergy  
1.5.5.1 Altered B7 Expression 
While T cells infiltrate gliomas, in both animal models and primary patient 
samples, they often lack cytotoxic activity and fail to produce IL-2. This 
observed T-cell anergy has been linked to defective antigen presentation 
and poor co-stimulation by tumor cells. Antigen presentation to CD8+T cells 
is decreased during glioma tumorigenesis due to the loss of HLA class I 
expression. Additionally, glioma cells express very low levels of B7 
costimulatory molecules [81]. Functional assays using heterogeneous ex 
vivo tumor preparations or pure populations of ex vivo tumor cells and 
microglia, demonstrated CD4+ T-cell activation only in the presence of 
exogenous B7 costimulation (provided by addition of soluble agonist anti-
CD28 monoclonal antibody). Therefore, to overcome immunosuppression 
in glioma, strategies need to overcome the low levels of B7 costimulation.  
 
1.5.5.2 STAT3 
Signal transducer and activator of transcription-3 (STAT3) has been 
identified as a major molecular hub of several signaling pathways in several 
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types of cancer including glioblastoma, breast, lung, ovarian, pancreatic, 
skin and prostate cancer [82, 83]. 
The binding of STAT3 to its gene targets affects proliferation, survival, 
differentiation and development. It is a member of the STAT family of 
cytoplasmic latent transcription factors. Receptor engagement by members 
of IL-6 cytokine family like IL-6, oncostatin M and Leukemia inhibitory 
factor, or growth factors like platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF) and epithelial growth factor (EGF) activate 
STAT3 by tyrosine phosphorylation. Kinases that induce STAT3 activation 
are receptor kinases like Janus kinase (JAK) family members associated 
with, FGFR, EGFR, PDGFR or nonreceptor-associated kinases like Ret, 
Src or Bcl-Abl. Postactivation STAT3 works to regulate expression of bcl2, 
bclxL, mcl1 and cyclinD1 among others.  
Other than promoting oncogenesis, active STAT3 also enables tumor 
growth by suppressing tumor recognition by the immune system [84]. 
STAT3 promotes tumor immune evasion by inhibiting pro-inflammatory 
cytokine signaling and amplifying Tregs. Inhibiting STAT3 activity by 
dominant-negative or antisense STAT3 expression increased expression of 
proinflammatory IFNγ, TNFα, IL-6, RANTES. STAT3 is also involved in 
maintaining immature dendritic cells and promoting tumor immune 
tolerance. Mice lacking STAT3 had elevated levels of MHC class II, CD80 
and CD86. Antitumor activity of T cells, NK cells and neutrophils was 
increased and dendritic cell maturation was enhanced by inhibition of 
STAT3 [85]. STAT3 activity was shown to be elevated in tumor-associated 
Treg cells that maintain tumor immune evasion. In these Treg, elevated 
activation of STAT3 increased proliferation and promoted expression of 
FoxP3, TGFβ and IL-10, all of which inhibit CD8+ T-cell differentiation, 
dendritic cell maturation and promote proliferation of Treg. 
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In gliomas, activation of STAT3 has been associated with the inhibition of 
T-cell response. Treg have been shown in the blood and within the tumor 
microenvironment of glioblastoma patients and are thought to contribute to 
the lack of effective immune responsiveness against glioblastomas. In a 
tissue microarray using tumor samples from 129 glioma patients, Abou-
Ghazal et al. showed correlation between prognosis of activated STAT3 
residues and tumor-infiltrating Treg [86]. Low incidence of activated STAT3 
was observed in normal brain or low-grade astrocytomas.  
 
1.5.5.3 PDL-1 
Programmed Death Ligand-1 (PDL-1) or B7-H1 is a member of the B7 
family and is a ligand for PD-1 (Programmed Death-1), a member of CD28 
family of T-cell regulators. B7-H1 is primarily inhibitory when expressed on 
tumors. It is significantly expressed on the surface of many human cancers, 
while undetectable in normal tissues [87]. B7-H1 is found to be highly 
expressed in carcinomas of colon, breast, ovarian, lung and melanoma 
cancer, oral squamous cell carcinoma, head and neck cancers and glioma 
among others [88-90]. The late downstream effects of signaling initiated 
through the B7-H1:PD-1 unidentified receptor network result in negative 
regulation of immune function [91]. The use of blocking monoclonal 
antibodies for B7-H1 or PD-1 increase cytokine production and antitumor 
CTL activity in experimental tumor models in mice [92]. 
Expression and immune regulatory activity of B7-H1 has been recently 
identified in human glioma cells in vitro and in vivo. In 12 different glioma 
cell lines, Wintrelle et al observed constitutive expression of B7-H1 mRNA 
[90]. High B7-H1 expression was observed in all 10 malignant glioma 
specimens upon immunohistochemical analysis, whereas no B7-H1 
expression could be detected on normal brain tissues. In conclusion, B7-H1 
may significantly influence the outcome of T-cell tumor interactions and 
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correspond to a novel mechanism by which glioma cells evade immune 
recognition and destruction. 
 
1.5.6 The induction of apoptosis  
1.5.6.1 Fas 
The induction of apoptosis is a key immune evasion strategy for multiple 
malignancies, including glioma. Fas/APO-1 is a cell surface receptor that 
mediates apoptosis when it reacts with Fas ligand (FasL) or anti-Fas 
antibody. The expression of Fas has been demonstrated on perinecrotic 
glioma cells, a histological hallmark of glioblastomas, suggesting a 
correlation between Fas expression and cell death [93]. Since glioma cells 
are not always able to turn off Fas expression they must use other 
strategies to evade Fas-induced apoptosis. A potential endogenous 
antagonist of Fas is soluble Fas which lacks the transmembrane domain. 
The soluble form of the Fas mRNA was detected in one anaplastic 
astrocytoma and in two glioblastomas [94]. Interestingly, some glioma cells 
co-expressed Fas and FasL suggesting that soluble Fas expression by the 
glioma cells prevented tumor cell-induced apoptosis. The expression of 
FasL by glioma cells may act as a glioma immune evasion mechanism.  
Apoptosis was induced in T cells by FasL+ tumor explants and tumor cell 
lines. According to Didenko et al, T cells that had undergone apoptosis 
expressed Fas and were colocalized with FasL-expressing tumor cells [95]. 
Since glioma cells have the ability to express both Fas and FasL, they have 
evolved mechanisms to prevent tumor cell apoptosis, while simultaneously 
inducing apoptosis in T cells.  
 
 
 
 
	  
35	  
1.5.6.2 CD70 
The expression of CD70 is a novel mechanism utilized by glioma cells to 
induce apoptosis in T cells and consequently evade the immune response. 
CD70, TNF-related cell surface ligand, is normally expressed on mature 
dendritic cells, activated T and B cells. The binding of CD70 to its cognate 
receptor CD27, is thought to play an important role in T-cell, B-cell and NK 
cell activation. CD27 is constitutively expressed by T cells, B cells and NK 
cells [96]. Signaling via CD27 by activated T cells is critical for survival and 
memory cell formation. In contrast, the ligation of CD27 has also been 
shown to induce apoptosis in activated T and B cells. CD27 costimulation 
has also been shown to enhance Treg function [97].  
CD70+ glioma cells were able to induce apoptosis in PBMC. In vitro 
experiments using glioma cells, in which Fas and TNFα were blocked, 
revealed that CD70 was sufficient to induce apoptosis in T cells [98].  
 
1.5.6.3 Gangliosides 
Tumor-derived gangliosides are important mediators of T-cell apoptosis 
and hence, they represent one mechanism by which tumors evade immune 
destruction [99]. Gangliosides are most highly expressed in cells of the 
CNS, where they comprise approximately 5-10% of the lipids. 
 
1.5.7 Recruitment of immunosuppressive lymphocytes  
1.5.7.1 Expression of chemokines 
Chemokines are a family of cytokines helping in the migration of responder 
cells by inducing directed chemotaxis. These proteins are very small in size 
(8-10 kDa) and have a characteristic two cysteine residues joined by 
disulfide bonds (cystine). The different members of chemokine family share 
gene sequence and amino acid homology. They are classified into several 
categories according to spacing of the cystine moieties that are key to 
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forming their 3-dimensional shape and accordingly, different families of 
receptors for these molecules have been described [100]. Their role has 
been implicated in various processes including angiogenesis and CNS 
development. Most importantly, chemokines play a central role within the 
immune system, as the secretion of these molecules leads to migration of 
leucocytes [101]. Chemokines appear to play a significant role in various 
diseases, including cancer. 
Chemokines is suspected to contribute to the process of the chronic 
inflammation that can predispose to cancer formation and progression 
[102]. Chemokines might also elicit an intrinsic effect on tumor cells. For 
instance, multiple human cancers including leukemias, lymphomas, 
gliomas and various epithelial carcinomas express CXC receptor 4 
(CXCR4) and respond to its ligand CXC ligand 12 (CXCL12). This ligand-
receptor interaction promotes the migration and metastatic establishment of 
tumor cells [103]. 
One of the initial reports of chemokines secretion by gliomas was made in 
2001 [104]. The authors demonstrated that human glioma cell lines secrete 
MCP-1 (CCL2) and IL-8 on stimulation with anti-Fas antibody or soluble 
Fas ligand in a time and dose-dependent manner. 
With regards to the tumoral migration of Treg, cancers express a series of 
chemokines that promote the infiltration by these regulatory lymphocytes. 
For instance, chemokine CCL22 promotes the migration of Treg into 
prostate and ovarian carcinomas [105]. 
In a work of 2008, Jordan JT et al [106] reported that human glioma cell 
lines express CCL22 in addition to CCL2, although only CCL2 was 
secreted by samples from GB patients. This has been investigated in the 
human glioma cell lines D-54, U-87, U-251 and LN-229 as well as in tumor 
cells from eight patients with GB. The authors further reported that Treg 
from these brain tumor patients had significantly higher expression of the 
CCL2 receptor CCR4 than the Treg from healthy controls. Migration 
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experiments have suggested that Treg migration is mediated by CCL2 and 
CCL22, which was blocked by antibodies to the chemokine receptors 
CCR2 and CCR4. 
1.5.7.2 Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSC) were originally named natural 
suppressors. These cells act independently of MHC interactions and inhibit 
the antigen-induced proliferation of T cells and antibody production by B 
cells. MDSC were isolated from the bone marrow of tumor patients and 
named for their ability to suppress T-cell proliferation [107].  
These cells lack expression of surface molecules characteristic of T, B, 
macrophage, or NK cells. Myeloid-derived suppressor cells are immature 
myeloid cells that have the potential to generate mature granulocytes, 
macrophages and dendritic cells. In mice, they are identified based on co-
expression of CD11b and Gr-1 [108]. Human MDSC equivalents are 
CD34+, CD33+, CD15- and CD13+, with variable expression of CD11c and 
HLA-DR and were originally identified in patients with head and neck 
cancer [109].  
Tumor-derived factors promoted MDSC recruitment and maturation into 
immunosuppressive cells and inhibited the differentiation of dendritic cells. 
Interestingly, glioma cells are known to produce both IL-6 and colony 
stimulating factor-1 (CSF-1), which may aid in the recruitment and/or 
expansion of MDSC in patients [110]. 
 
1.5.7.3 Regulatory T cells 
Regulatory T cells (Treg; CD4+ CD25+ FOXP3+) are a fraction of the T-cell 
population that suppress immune activation and thereby maintain immune 
system homeostasis and tolerance to self-antigens. Functional depletion of 
Treg cells induces autoimmunity, facilitate transplantation tolerance and 
also increases immunity to tumors. Treg cells consist of 1-10% of total 
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CD4+T cells in thymus, peripheral blood and lymphoid tissues and could 
conceivably recognize a wide spectrum of self and nonself antigens [111]. 
Treg development takes place directly in the thymus and leave thymus as 
mature with defined phenotype. This is unlike the development of other T-
cell subsets, which are induced upon antigen exposure. They are 
dependent on IL-2 stimulation for their development, peripheral expansion 
and suppression function. Blocking the IL-2R on Treg cells leads to a loss 
of their regulatory activity, suggesting a possible role for IL-2 for suppressor 
function. IL-2 may be required in the production of Treg and alterations in 
this pathway may block Treg cell development. Functionally, IL-2 promotes 
proliferation and survival in T cells either by activating the signal transducer 
and activator of transcription 5 (STAT5), a transcription factor, or by up-
regulation of anti-apoptotic molecules, Bcl-2 [112]. Treg express forkhead 
box P3 (FoxP3), a transcription factor that plays a central role in defining 
their function [113]. FoxP3 is essentially expressed in CD4+ CD25+ CD8- 
thymocytes but not in any other thymic cells. FoxP3 deficient mice suffer 
from autoimmune symptoms and die from inflammatory diseases In 
humans, Type I diabetes, thyroiditis and inflammatory bowel diseases is 
associated with mutations on the FoxP3 gene. Existence of other 
populations of T regulatory lymphocytes has been reported in recent 
publications.  
The precise means by which Treg suppress effector T-cell-mediated 
immune responses have not been definitively characterized. Some studies 
suggest roles of cytokines in their regulation and others support the 
contribution of cell-to-cell contact with effector T cells on APC, where 
membrane bound TGFβ and cytotoxic T-lymphocyte protein (CTLA-4) plays 
an important role [114]. 
An increased fraction of Tregs has been reported to infiltrate the tumor 
contributing to the immunodeficient status associated with glioma [110]. A 
lack of immune rejection of neoplastic cells is believed to be maintained by 
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Treg in many malignancies including colorectal, esophageal, pancreatic, 
breast, lung, ovarian and brain tumors [115-118]. It is therefore very 
important to understand the biology and function of Treg for its potential 
therapeutic benefits. 
In 2006, a study was reported from the Heimberger laboratory [119]. GB 
patient tumors were analyzed for glioma-infiltrating microglia/macrophage 
(GIM) and their effect on antitumor immune responses. The authors 
revealed that GIMs failed to induce T-cell proliferation. They demonstrated 
a corresponding lack of effector/activated T cells and there was a 
prominent population of Treg (CD4+CD25+FoxP3+) infiltrating the tumor. 
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1.6 Active Immunotherapy, an attractive approach against 
cancer. Dendritic cells- and peptide-based vaccination 
1.6.1 Introduction 
There are increasing numbers of reports demonstrating that systemic 
immunotherapy using dendritic cells (DC) is capable of inducing an 
antitumor response within the immunologically privileged brain, confirming 
that the CNS may not be an absolute barrier to DC-based immunotherapy 
[120-122]. Therefore, the possibility that the immune system can mediate 
interactions with lesions in brain tumors suggests excellent potential for 
investigating novel immunotherapies. For example, DC-based 
immunotherapy might be a new treatment modality for patients with brain 
tumors. To induce an antitumor immune response against glioma cells, 
antigen presenting cells (APCs) such as DC may be required to efficiently 
internalize, process and present glioma-specific antigens to the immune 
system [123]. 
 
1.6.2 DC in immunobiology 
The immune system has evolved as a highly complex and adaptive 
mechanism to distinguish non-self and self. Foreign cells, including host 
cells bearing intracellular pathogens, are recognized and destroyed by 
cellular immune responses, which depend on the T-cell receptor for specific 
recognition of cell-surface antigens. T cells that directly kill foreign cells are 
commonly CD8+, generally recognizing a cell-surface complex of major 
histocompatibility complex (MHC) Class I molecules and foreign peptides 
derived from intracellular proteins processed in the foreign cells through a 
cytoplasmic pathway. 
DC are rare, hematopoietically derived leukocytes that form a cellular 
network involved in immune surveillance, antigen capture and antigen 
presentation [123]. DC can differentiate from both myeloid precursors and 
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peripheral blood monocytes, maturing and migrating via the afferent 
lymphatics to T-cell-rich areas of draining lymph nodes and the spleen 
where they develop antigen-presenting function. DC that have encountered 
antigens have been shown to undergo maturation that renders them 
capable of migrating to regional lymph nodes and activating antigen-
specific T cells [124]. Activated DC express high levels of Class I and II 
MHC antigens, as well as adhesion molecules (CD11a and CD54) and 
accessory molecules (CD40, CD80 and CD86). 
During the maturation process, they lose their ability to process and present 
soluble antigen and become extremely potent stimulators of T-lymphocytes 
[125]. It has now become clear that DC may play an important supportive 
role in promoting and maintaining antigen-specific T cells in vivo. Although 
DC play central roles in immunity, they also have a critical role in 
maintaining self-tolerance. DC are unique, highly potent APCs capable of 
sensitizing naive CD4+/CD8+ cells [126]. While CD8-T cells are critical 
effectors in antitumor immune responses, CD4+ T cells also have an 
important role. Possible mechanisms by which CD4+ T cells may promote 
antitumor cytotoxic T cells (CTL) development and function include 
production of cytokines such as interferon (IFN)-γ, modification of DC and 
maintenance of CD8+T-cell numbers. Originating from CD34 + bone marrow 
stem cells, human DC precursors are found in the bone marrow as well as 
peripheral blood and, in a more mature form, in lymphoid and non-lymphoid 
tissues. Currently, three different subtypes of DC have been defined: 
Langerhans cells, interstitial DC and plasmacytoid DC.  
Candidate APCs in the CNS include parenchymal cells, such as astrocytes, 
oligodendrocytes and endothelium and nonparenchymal hematogenous-
derived immune cells including microglia, perivascular macrophages, other 
macrophage populations and DC [127]. 
Macrophages in the leptomeninges and choroid plexus perform a variety of 
functions in common with other tissue macrophages, such as removing 
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tissue debris from the CSF in the subarachnoid space, which would 
otherwise cause obstruction to the CSF drainage pathways. 
 
1.6.2 DC in tumor immunology 
The ability of DC to initiate or regulate immunity has led to the study of their 
use as cellular vaccine adjuvants for the immunotherapy of cancer [Fig. 5]. 
With techniques available for the isolation and bulk propagation of DC in 
vitro, great efforts have been made to use DC in various immunization 
strategies. [128]. 
DC are efficient at recruiting, selecting and expanding naive T cells with 
antigen specificity within lymphoid organs. These T cells may be exported 
into tumor sites as immune effectors capable of directly killing targets and 
releasing several cytokines that facilitate additional immune responses. DC 
can sensitize both CD4+ and CD8+ T cells to specific antigens, while CD4+ 
T cells are critical for priming CTL. Therefore, both CD4+ and CD8+ T cells 
are equally important in tumor immunology. 
Many strategies for delivering antigens into DC have been established in 
murine models and are now undergoing evaluation in clinical trials. These 
include the use of synthetic peptides where the tumor antigen is known 
[129, 130], stripped peptides derived from Class I molecules from tumors 
[131], tumor RNA [132] and tumor lysates [133,120]. 
The advantages of vaccinating with total tumor-derived material, such as 
tumor cell lysates or tumor-derived mRNA, are that the identity of the tumor 
antigens need not be known and the use of multiple tumor antigens 
reduces the risk of developing antigen-negative escape mutants. Another 
promising and efficient approach is by using cells produced by the fusion of 
DC and tumor cells as a vaccine [134]. 
DC are equipped with a sophisticated molecular array of cell components 
representing the antigen-processing machinery (APM). The APM is 
 
	  
43	  
essential for the uptake and processing by DC of tumor-derived antigens, 
allowing tumor-derived epitopes to be cross-presented to T cells. The ability 
of DC to traffic and to localize in appropriate regions of lymphatic tissues is 
critical for the success of DC-based vaccines. Most clinical trials manipulate 
DC through ex vivo culture to assure accurate antigen delivery and DC 
activation. DC are typically administered intradermally, intravenously, or, in 
special circumstances, intraperitoneally.  
Human tumors express a variety of protein antigens recognizable by the 
immune system and these antigens are potential targets for cancer 
vaccination therapy. Unfortunately, the tumor antigens are self-derived and 
are generally considered weak antigens. Selection of tumor antigen and 
appropriate loading of in vitro-generated DC with the antigen is an initial 
and crucial step in the development of an efficient DC-based cancer 
vaccine. DC-based therapy in patients with cancer has now progressed to 
Phase II trials. With the safety of DC transfers established, the challenge of 
the ongoing clinical studies will be to determine effective therapeutic doses 
and to obtain evidence for clinical efficacy for this form of immunotherapy. 
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Fig. 5 Critical role of dendritic cells (DCs) in generating vaccine-induced antitumor immune responses. 
Cancer vaccines consist of many diverse formulations, in which antigen is in form of protein or peptide, 
recombinant virus or bacterium, or engineered tumor cell. Ultimately, antigen must be targeted to DCs (1). For 
cancer vaccine to be effective, DCs must be activated, either through incorporation of pattern-recognition 
receptor (PRR) agonist into vaccine or via activation properties of vector (ie, virus or bacterium). Ideal viral or 
bacterial vaccine vectors can infect DCs and, in so doing, activate them (2). Steps 1 and 2 can be 
accomplished ex vivo, as with DC vaccines (ie, sipuleucel-T). Activated DCs loaded with tumor antigen traffic 
to draining lymph node via afferent lymphatics (3). In lymph node, they present processed antigen to T cells 
along with costimulatory signals in form of cytokines and membrane ligands, thereby activating tumor-specific 
T cells (4) that are otherwise in tolerant state. Activated T cells leave draining lymph nodes via efferent 
lymphatics (5) and ultimately enter bloodstream via thoracic duct. They exit bloodstream in peripheral tissues, 
where they seek out and recognize tumor deposits expressing cognate tumor antigen and exert antitumor 
effects (6) (Topalin SL, 2011). 
 
1.6.4 Clinical trials of DC-based vaccines 
There are several reports concerning clinical trials of DC based vaccines 
for patients with glioma. The antigen sources in the trial varied from 
peptides eluted from autologous glioma cells, fusions of DC and tumor 
cells, to tumor lysates. 
Yu et al [135] reported a Phase I clinical trial of DC pulsed with peptides 
eluted from autologous glioma cells. Two patients had recurrent anaplastic 
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astrocytoma (AA) and 7 glioblastoma (GB). Peptide-pulsed DC were 
injected intradermally in the deltoid region 3 times biweekly. DC vaccination 
elicited systemic cytotoxicity in seven patients and intratumoral cytotoxic 
and memory T-cell infiltration was detected in two patients. This Phase I 
study demonstrated the feasibility, safety and bioactivity of DC vaccines. 
Liau et al [136] also reported a Phase I clinical trial of DC pulsed with 
peptides eluted from autologous glioma cells. Twelve GB patients were 
enrolled and three biweekly intradermal vaccinations were given. There 
were no serious adverse events observed and six patients developed 
systemic antitumor CTL responses. Unfortunately, the induction of systemic 
effector cells did not translate into objective clinical responses, particularly 
for patients with actively progressing tumors and/or those with tumors 
expressing high levels of TGFβ. 
Yu et al [137] reported another Phase I trial of DC pulsed with tumor lysates 
of autologous glioma cells. Four patients had recurrent AA and 10 GB. Six 
of 10 patients demonstrated robust systemic cytotoxicity as demonstrated 
by IFNγ expression by peripheral blood mononuclear cells (PBMC) in 
response to tumor lysates after vaccination. The median survival for 
patients with recurrent GB in this study was 133 weeks. 
Rutkowski et al [138] reported a Phase I trial of DC pulsed with tumor 
lysates of autologous glioma cells. One patient had recurrent AA and 11 
GB. There were no serious adverse effects, with no clinical or radiological 
evidence of autoimmune reactions in any of the patients in these studies, 
with the exception of 1 patient who repetitively developed peritumoral 
edema. Two of the 6 patients with complete resection are still showing a 
continuous complete response (CR) after 3 years.  
Liau et al [139] have reported a tumor lysate-pulsed DC vaccine in 
combination with the TLR-7 agonist, Imiquimod, following radio-
chemotherapy for newly diagnosed GB. Thirteen patients received 3 
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immunizations at 2-week intervals, following completion of a 6-week course 
of radio-chemotherapy. Patients without tumor progression received 
booster vaccinations combined with topical administration of the Imiquimod. 
All immunizations were well tolerated, with only mild side effects. Increased 
levels of CD8+ T cells reactive against tumor antigens were detected in 5 
patients. The median progression free survival (PFS) is 18.1 months and 
median overall survival (OS) is 33.8 months. Newly diagnosed GB patients 
are currently enrolling for a multi-centre Phase II trial to test the efficacy of 
their autologous DC vaccine.  
Kikuchi et al [140] reported on immunotherapy involving fusions of DC and 
glioma cells. Three patients had recurrent AA and 5 GB. Clinical results 
showed that there were no serious adverse effects and 2 partial responses 
(PRs).  
Kikuchi et al [141] also reported another immunotherapy with fusions of DC 
and glioma cells combined with recombinant IL-12. Nine patients had 
recurrent AA and 6 GB. Clinical results showed that there were no serious 
adverse effects, 4 PRs and 1 minor response (MR) in patients with AA. 
Yamanaka et al [142, 143, 143a] reported on therapy using DC pulsed by 
tumor lysates. Twenty-four patients with recurrent malignant glioma (6 
Grade III and 18 Grade IV patients) were evaluated in a Phase I/II clinical 
study. DC were injected intradermally, or both intratumorally and 
intradermally every 3 weeks. The protocols were well tolerated with only 
local redness and swelling at the injection site in several cases, while 
clinical responses showed 1 patient with PR and 3 MRs. Increased 
ELISPOT and DTH responses after vaccination provided good laboratory 
markers to predict the 
clinical outcome of patients receiving DC vaccination. The OS of patients 
with GB was 480 days, which was significantly better than that in the 
control group. 
Wheeler et al [144] reported a Phase II trial of DC pulsed with tumor lysates 
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of autologous glioma cells. Thirty-four GB patients were enrolled. 
Seventeen patients exhibited a positive vaccine response quantified by 
IFNγ responsiveness after three vaccinations. Vaccine responders 
exhibited significantly longer post treatment times to tumor progression 
(TTP) and survival (TTS) relative to non responders. Vaccine-induced 
responses elicited therapeutic benefits primarily by sensitizing tumors to 
chemotherapy. 
Vleeschouwer et al [145] reported a Phase II trial of DC pulsed with tumor 
lysates of autologous glioma cells. Fifty-six patients with relapsed GB were 
treated with at least three vaccinations. The median PFS and OS were 3 
and 9.6 months, respectively, with a 2-year OS of 14.8%. Vaccine-related 
edema in one patient with gross residual disease before vaccination was 
the only serious adverse event. 
In a recent work of my group, Pellegatta et al [146] reported the possible 
benefits of an immunotherapeutic strategy based on mature dendritic cells 
(DC) loaded with autologous tumor-cell lysates in 15 patients affected by 
recurrent GB. The median progression-free survival (PFS) of this patient 
cohort was 4.4 mo, and the median overall survival (OS) was 8.0 mo. 
Patients with small tumors at the time of the first vaccination (< 20 cm3; n = 
8) had significantly longer PFS and OS than the other patients (6.0 vs. 3.0 
mo, p = 0.01; and 16.5 vs. 7.0 mo, p = 0.003, respectively). CD8+ T cells, 
CD56+ natural killer (NK) cells and other immune parameters, such as the 
levels of transforming growth factor β, vascular endothelial growth factor, 
interleukin-12 and IFNγ, were measured in the peripheral blood and serum 
of patients before and after immunization, which enabled us to obtain a 
vaccination/baseline ratio (V/B ratio). An increased V/B ratio for NK cells, 
but not CD8+ T cells, was significantly associated with prolonged PFS and 
OS. Patients exhibiting NK-cell responses were characterized by high 
levels of circulating IFNγ and E4BP4, an NK-cell transcription factor. 
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Furthermore, the NK cell V/B ratio was inversely correlated with the TGFβ2 
and VEGF V/B ratios. These results suggest that tumor-loaded DC may 
increase the survival rate of patients with recurrent GB after effective tumor 
debulking, and emphasize the role of the NK-cell response in this 
therapeutic setting. 
DC based strategies appear promising as an approach to successfully 
induce antitumor immune responses and prolong survival in patients with 
glioma. DC therapy of glioma seems to be safe and without major side 
effects, thus its efficacy should be determined in randomized and controlled 
clinical trials. Every patient with glioma will be evaluated for the molecular 
genetic abnormalities in their individual tumors and novel 
immunotherapeutic strategies based on pharmacogenomics will be offered 
according to the genetic findings. 
 
1.6.5 Peptide-based immunotherapy in glioma 
Recent advances in molecular biology and tumor immunology have 
resulted in the identification of a large number of tumor-associated antigens 
(TAA) that could be used for cancer vaccination, since their epitopes 
associated with HLA class I molecules were recognized by cytotoxic T-
lymphocytes (CTL). 
Peptide-based vaccines represent a major focus of cancer vaccine 
research that offers exciting clinical possibilities. Peptides used as cancer 
vaccines usually consist of introducing small peptides (typically 7-14 amino 
acids in length) that are immunologic and expressed by targeted cells [147, 
148]. Peptides are capable of binding to a particular HLA class I antigen. 
Such peptides are processed by host antigen presenting cells (APC), which 
travel to the lymph nodes and sensitize circulating T-lymphocytes, known 
as cytotoxic T cells (CTL) [Fig. 6]. 
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Fig. 6 Peptide-based immunotherapy. The schematic overview depicts the idealized vaccination-induced 
peripheral priming of a tumor-specific immune response. After peptide uptake and processing peripheral 
antigen presenting cells, especially dendritic cells, present the antigen via HLA-class I and -II molecules to 
tumor-specific T cells. After TCR-peptide: HLA and costimulatory molecule-induced activation, T cells 
proliferate and execute their effector functions. CD4 + T helper cells promote the perpetuation of the mounted 
immune response by activating local antigen presenting cells (APC), while CD8 + cytotoxic T cells directly lyse 
tumor cells through induction of apoptosis by, i.e. perforin, granzyme and granulysin. Glioblastoma cells try to 
evade immune-mediated lysis by attracting regulatory T cells, thereby promoting an anti-inflammatory milieu. 
 
A peptide suitable for the individual patient is generally mixed with an 
adjuvant followed by subcutaneous administration every 7-14 days to form 
a vaccine. CTL recognizing a peptide on APC become activated in 
association with clonal expansion in the nodes. These activated CTL come 
out through lymph nodes or blood circulation, migrate and infiltrate into the 
brain, recognize the corresponding peptide-HLA complex on glioma cells 
and eliminate glioma cells, which in turn results in tumor regression. 
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Several clinical trials of peptide-based immunotherapy for cancer have 
been conducted in the past decade, but major clinical responses were 
rarely obtained [149]. Recently, objective responses for peptide 
vaccinations including WT1 peptide [150, 151], personalized peptide and 
EGFRvIII peptide [64] are obtained and reported. These clinical trials for 
malignant gliomas were reviewed in this chapter. 
 
1.6.5.1 EGFRvIII-peptide vaccination 
The majority of glioblastoma cases harbor mutations in the Epidermal 
Growth Factor Receptor (EGFR). In particular, the epidermal growth factor 
receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is 
widely expressed in malignant gliomas and other neoplasms. This mutation 
encodes a constitutively active tyrosine kinase that enhances tumorgenicity 
and migration and confers radiation and chemotherapeutic resistance. The 
EGFRvIII mutation arises from an in-frame deletion/ fusion that results in 
constitutively active EGF signaling. This in-frame deletion mutation splits a 
codon resulting in the creation of a novel glycine at the fusion junction 
between normally distant parts of the molecule and producing a sequence 
re-arrangement which creates a tumor-specific epitope for cellular or 
humoral immunotherapy in patients with malignant gliomas.  
An EGFRvIII-specific peptide that spans this deletion/fusion has shown to 
be an immunogenic antigen [64] and was found to be an attractive target 
antigen for immunotherapy against malignant gliomas. In a Phase I clinical 
trial conducted at Duke University, 20 patients of malignant glioma were 
enrolled and vaccinated with the EGFRvIII peptide. Following surgical 
resection, each patient underwent leukapheresis to obtain peripheral blood 
mononuclear cells (PBMC) for autologous mature DC generation and 
baseline immunologic monitoring. Three patients with anaplastic 
astrocytomas and 13 patients with glioblastomas were vaccinated. 
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DC were pulsed for 2 h, with 500 µg of EGFRvIII-specific peptide, PEPvIII 
(LEEKKGNYVVTDHC) (Multiple Peptide Systems, San Diego CA) which 
was conjugated 1:1 with keyhole limpet hemocyanin (KLH) (Biosyn, 
Carlsbad, CA). The first 3 patients received 3 x 107 mature DC per 
vaccination intradermally beginning 2 weeks following completion of 
radiation therapy, the remaining patients received one-third of their total 
generated DC per injection (up to 1.1 x 108 cells). 
The unique EGFRvIII junctional peptide has been utilized as a peptide 
vaccine to promote anti-tumor host immune responses against EGFRvIII-
positive tumors [152]. Rodents challenged with EGFRvIII-positive cells 
subcutaneously or intracerebrally displayed significant tumor reduction and 
increased survival rates following administration of DC loaded with an 
EGFRvIII synthetic peptide conjugated to keyhole limpet hemocyanin (KLH) 
[153] or with EGFRvIII–KLH only [154]. 
Only a few trials have reported on EGFRvIII-specific therapy in glioma 
patients. Two clinical trials using vaccines against EGFRvIII have enrolled 
newly diagnosed malignant glioma and GB patients, and encouraging 
results have been reported [65, 155].  
The first study evaluated the safety and immunogenicity of a DC-based 
vaccine targeting the EGFRvIII antigen. Patients with newly diagnosed GB 
after surgery and radiotherapy received intradermal vaccinations with 
autologous mature DC pulsed with an EGFRvIII-specific peptide conjugated 
to KLH. No allergic reactions or serious adverse events were encountered. 
EGFRvIII-specific immune responses were evident in most patients. 
Median time to progression from vaccination was 6.8 months (95% CI: 2.5-
8.8), and median survival time was 18.7 months from vaccination and 22.8 
months from time of histological diagnosis.  
The second study was a Phase II trial that investigated the immunogenicity 
of an EGFRvIII peptide vaccine and the survival in patients with newly 
diagnosed, EGFRvIII-expressing GB and minimal tumor burden. 
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Intradermal vaccinations were administered until tumor progression. The 
6-month progression-free survival (PFS-6) rate after vaccination was 67 
and 94% after diagnosis. The median OS was 26.0 months greater than 
that observed in a control group matched for eligibility criteria, prognostic 
factors, and temozolomide treatment (p= 0.0013). The development of 
specific antibody (p= 0.025) or delayed-type hypersensitivity (p= 0.03) 
responses to EGFRvIII had a significant effect on OS.  
Strikingly, at recurrence, 82% of patients had lost EGFRvIII expression (p= 
0.001). Thus, the results of this trial provide the first evidence of the 
relevance of tumor immunoediting in shaping immune responses to glioma 
[156]. The disappearance of EGFRvIII-positive cells after immunotherapy 
indicates that the immune system primed against cells expressing the 
EGFRvIII peptide may kill them effectively. In spite of this the tumor may 
survive: this may be due to continued EGR signaling due to EGFR 
amplification in the absence of EGFRvIII. Data on maintained amplification 
of EGFR were not available in the manuscript by Sampson et al. Thus, 
investigation on the EGFR pathway of relapsing tumors after EGFRvIII 
peptide vaccination will provide important hints on the relevance, 
redundancy and flexibility of this critical pathway of tumorigenesis. Recent 
data have shown a deletion of the NFKBIA gene in approximately 22% of 
GB [157]. This deletion is usually absent in GB with EGFR amplification, 
suggesting that NF-kB deletion can substitute for EGFR amplification in the 
pathogenesis of GB. The observation prompts the study of the NF-kB 
status in GB before and EGFRvIII peptide immunotherapy treatment and 
consequent immunoediting. 
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1.7 Stem cells, radial glial cells, and a unified origin of brain 
tumors 
1.7.1 Neural stem cells and the origin of brain tumors 
As described in chapter 1.3.2, neural stem cells (NSC) have been 
implicated not only in brain development and neurogenesis but also in 
tumourigenesis; GB can be initiated from alterated neural stem-like cells.  
The origin of NSC is still unclear, however a recent hypothesis suggests 
that they might originate from radial glial cells, primary embryonic stem 
cells derived from neuroepithelial cells [158]. Adult stem cells are defined 
as cells giving rise to daughter cells with equal developmental potential 
(self-renewal) and capable to generate all differentiated cell types in a given 
tissue (multipotency in most cases; unipotency e.g. in a spermatogenic 
stem cell). Cells with stem cell properties have been identified in four 
distinct anatomical areas of the postnatal mammalian brain: (i) the 
subventricular zone (SVZ) beneath the lateral wall of the lateral ventricles, 
(ii) the subgranular zone (SGZ) in the dentate gyrus of the hippocampus, 
and more recently also (iii) in the subcallosal zone (SCZ) between the 
hippocampus and the corpus callosum [159] and (iv) in the cerebellum at 
the boundary between internal granular layer (IGL) and white matter. 
There is now evidence that all brain tumors originate from a special type of 
stem cell called the “radial glial cell” (RGC). Currently, the consensus of 
opinion is that most brain tumors also originate from the so-called “brain 
tumor stem cells” (BTSC) (of which RGCs are a subtype) [160]. When brain 
tumor stem cells mutate (4–7 mutations are needed before degeneration 
occurs), they can generate phenotypically diverse tumors. Within a specific 
tumor, brain tumor stem cells constitute only a small fraction of the total 
malignant cells [161]. 
It is interesting to note that in the human brain, most stem cells are located 
in the SVZ. Both supra- and infratentorially and when stimulated with 
carcinogens, cells in the SVZ become tumorigenic faster than those located 
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elsewhere. In the SVZ, stem cells exist in the form of RGC. RGC remain 
quiescent until they receive transformational signals. It is not clear if RGC, 
after receiving transformation signals, return to their initial stem cell 
configuration and then become tumorigenic or if they transform to tumor 
progenitor cells directly [162]. 
 
1.7.2 Inside the radial glia 
Radial glial cells are a widespread cell type throughout the developing CNS 
of vertebrates [Fig. 7]. They are best known for their role in guiding 
migrating neurons [163] and a precursors during neurogenesis [164]. They 
arise early in development from neuroepithelial cells. Radial phenotype is 
typically transient, but some cells, such as Bergmann glia in the cerebellum 
an Müller glia in the retina, retain radial glia-like morphology postnatally. 
According to recent research, during the late stages of cortical 
development, radial glial cells divide asymmetrically in the ventricular to 
generate radial glial cells, postmitotic neurons and intermediate progenitor 
cells. Intermediate progenitor cells then divide symmetrically in the 
subventricular zone  to generate neurons. During gliogenesis, radial glial 
cells differentiate into astrocytes [165]. 
The term radial glial cell refers to their two major characteristics, their long 
radial processes extending from the ventricular zone (VZ) to the pial 
surface and their glial properties, such as the content of glycogen granules 
or the expression of the astrocyte-specific glutamate transporter (GLAST) 
or the glial fibrillary acidic protein (GFAP) [163, 166]. Another radial glia-
specific protein is the brain lipid binding protein (FABP7), expression of 
which could be induced by Notch-1 activation, in particular, when acted 
upon by reelin. Interestingly, Notch-1, then activated before birth, induces 
radial glia differentiation, but postnatally induces the differentiation into 
astrocytes [167]. Very interesting Pellegatta and colleagues performing 
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gene expression profile analysis on CSC, identified several up-regulated 
genes related to the Radial Glia. In particular GLAST and FABP7 are highly 
expressed in murine (GL261) and human glioma stem-like cells (GSC) 
[168]. In another study of De Rosa et al [169], FABP7 was identified as one 
of the most highly expressed genes in neurospheres cells from GB 
compared to their adherent counterpart. The authors found that down-
regulation of FABP7 expression in NS by small interfering RNAs 
significantly reduced cell proliferation and migration. In vivo reduced 
tumorigenicity of GB cells with down-regulated expression of FABP7 was 
associated to decreased expression of the migration marker doublecortin. 
These data emphasize the role of FABP7 expression in GB migration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 Unified hypothesis for neural stem-cell development. Left panel: Neural stem cells (purple) in the 
early neuroepithelium extend from the ventricle to the pia. Middle panel: Like neuroepithelial stem cells, many 
radial glia (purple) also contact the ventricular and pial surfaces. Radial glia might be neural stem cells, 
perhaps an elongated form of the neuroepithelial cell. Radial glia are known to divide symmetrically (not 
shown) or asymmetrically (arrows) to produce neurons (red) that migrate into the cortex along the fibre of their 
progenitor. Radial glia might produce neurons directly or indirectly through transit amplifying cell types (green). 
Right panel: Radial glia transform into cortical astrocytes later in development. Cells derived from radial glia 
might come to reside in the adult subventricular zone (SVZ) (blue). Like radial glia and neuroepithelial cells, 
some SVZ astrocytes contact the ventricle and extend a short 9+0 cilium into the cerebrospinal fluid. These 
astrocyte-like cells behave as stem cells in that they self-renew and produce neurons (arrows), possibly 
through intermediate cell types (green) (Alvarez-Buylla A et al, 2001). 
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1.8 Glutamate signalling in physiological and pathological brain 
1.8.1 Introduction 
Glutamate, a nonessential amino acid, is the major excitatory 
neurotransmitter in the central nervous system. As such, glutamate has 
been shown to play a role in not only neural processes, such as learning 
and memory, but also in bioenergetics, biosynthetic and metabolic 
oncogenic pathways.  
Glutamate has been the target of intense investigation for its involvement 
not only in the pathogenesis of benign neurodegenerative diseases (NDD) 
such as Parkinson’s disease, Alzheimer’s disease, schizophrenia, multiple 
sclerosis, and amyotropic lateral sclerosis (ALS), but also in carcinogenesis 
and progression of malignant diseases. In addition to its intracellular 
activities, glutamate in secreted form is a phylogenetically conserved cell 
signaling molecule. Glutamate binding activates multiple major receptor 
families including the metabotropic glutamate receptors (mGluRs) and 
ionotropic glutamate receptors (iGluRs), both of which have been 
implicated in various signaling pathways in cancer. Inhibition of extracellular 
glutamate release or glutamate receptor activation via competitive or non-
competitive antagonists decreases growth, migration and invasion and 
induces apoptosis in breast cancer, melanoma, glioma and prostate cancer 
cells. In this chapter, I discuss the current state of glutamate signaling in 
brain and notions regarding glutamate involvement in brain cancer. These 
findings provide the notions that glutamate and/or glutamate transporter 
would be a interesting target of anti cancer therapies especially in gliomas. 
 
1.8.2 Overview on glutamatergic neurotransmission 
The amino acid glutamate is recognized as the primary excitatory 
neurotransmitter in the mammalian central nervous system (CNS). 
However, recent developments have shown that glutamate receptors are 
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broadly expressed in tissues other than the brain by cells that have not 
traditionally been associated with glutamate-mediated signalling. For 
example, the proliferation of several tumour cells is highly sensitive to 
glutamate receptor antagonists [169].  
Glutamate was originally speculated to serve a metabolic function in the 
CNS [170], as it was found within numerous intracellular compartments 
including the cytosol and mitochondria of all CNS cell types. However, it is 
now known that despite its ubiquitous nature, levels of extracellular 
glutamate are indeed tightly regulated, thus allowing glutamate to function 
as the major excitatory neurotransmitter in the mammalian CNS. The tight 
control of glutamatergic neurotransmission is an energy-costly process, 
requiring multiple regulatory processes and high levels of glucose and 
oxygen consumption. 
It is important to note that in addition to its role as a neurotransmitter, 
glutamate also serves as a metabolic precursor to GABA and as a 
component of various amino acid-based derivatives, e.g. the antioxidant 
glutathione. Consistent with glutamate's key role in multiple aspects of brain 
physiology, metabolic studies have determined that virtually all of the 
glucose that enters the CNS is eventually converted to glutamate 
Cytosolic glutamate crosses the vesicular membrane via the activity of 
vesicular glutamate transporters (VGLUTs) [171]. VGLUTs are multimeric 
proton/glutamate antiporters. The loss of VGLUT expression via targeted 
knockout strategies results in the loss of glutamate packaging into synaptic 
vesicles and deleterious neuropsychiatric sequelae [172]. In a Ca2+ and 
soluble N-ethylmaleimide sensitive factor attachment protein receptor 
(SNARE)-dependent manner [173, 174], glutamate is released into the 
synaptic cleft to bind to and elicit its effects on postsynaptic receptors. 
Dysregulated excitatory neurotransmission, resulting in high concentrations 
of extracellular glutamate, and especially increased levels of extrasynaptic 
glutamate, leads to cellular damage (hence, the term “excitotoxicity”) [175, 
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176]. Fast synaptic transmission is mediated by a-amino-3-hydroxy-5-
methyl-4-isoaxazolepropionate acid receptor (AMPA-R), whereas N-methyl-
D-aspartate receptor (NMDA-R) activation is typically implicated in 
coincidence detection and associative learning. In addition, both neurons 
and glial cells express metabotropic glutamate receptors that couple to 
various second messenger pathways. 
Following binding to synaptic glutamate receptors (Glu-R), Glu is either 
transported back into presynaptic neuronal terminals or taken up into 
nearby glial cells. Glial Glu uptake appears to be the predominant route for 
the degradation of Glu from the synaptic space making it among the most 
recognized functions of non-malignant astrocytes. Glu clearance occurs 
primarily via one of two Na+-dependent transporters [Fig. 8]. They are 
localized in close proximity of glutamatergic synapses. In fact, throughout 
the CNS, most glutamatergic synapses are tightly ensheeted by astrocytic 
processes placing their Glu transporters near synaptic release sites. It is 
generally believed that this arrangement ensures the rapid and effective 
containment of Glu spillage out of the synaptic cleft. 
Five such high-affinity transporters have been identified to date [177]. 
EAAT1 (GLAST) is abundantly detected in the neocortex and cerebellum 
but appears to be restricted to astrocytes. EAAT2 (GLT-1), the chief 
glutamate transporter in the forebrain, is expressed mostly in astrocytes but 
also, to a limited extent, in neurons. EAAT3 (EAAC1) is neuron-specific and 
enriched in GABAergic presynaptic nerve endings. EAAT4 has only been 
detected in the dendrites of cerebellar Purkinje neurons. Finally, EAAT5 is 
retina-specific. The location of the EAATs relative to the geometry of 
synapse places them in a critical position to prevent glutamate spillover and 
activation of extrasynaptic glutamate transporters [178].  
Considering individual astrocytes serve large numbers of synapses with 
minimal overlap in the synapses served by neighboring astrocytes, the 
failure of a single astrocyte could impair glutamate removal at thousands of 
 
	  
59	  
synapses in some brain regions. Interestingly, dysfunction of EAATs has 
specifically been implicated in the pathology of several neurodegenerative 
disorders [179]. 
Once in the cytosol, glutamine synthetase, an astrocyte and 
oligodendrocyte-specific enzyme, converts glutamate into glutamine in an 
ATP-requiring reaction with ammonia. Both astrocytes and neurons contain 
glutamine transporters that, under appropriate electrophysiological 
conditions, lead to the net exchange of glutamine from astrocytes-to 
neurons. In neurons, the mitochondrial phosphate-specific enzyme, 
glutaminase, reconverts inert glutamine-to-glutamate for subsequent 
repackaging into synaptic vesicles. The cycling of glutamate/glutamine in 
astrocytes and neurons has been termed “the glutamine cycle” 
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Fig. 8 Glutamatergic neurotransmission. Due to the risk of excitotoxic damage in the wake of excessive 
glutamatergic stimulation, precise physiological control of glutamate must be maintained in the mammalian 
CNS. Glutamine (Gln) is converted to glutamate (Glu) by glutaminase [though glutamate may also be derived 
from the TCA cycle (not shown)]. Glu is packaged into presynaptic vesicles by vesicular Glu transporter 
(VGLUT) proteins and synaptically released in a voltage-dependent manner through vesicular interactions with 
SNARE proteins. Synaptically-released Glu is recycled from the extracellular space by excitatory amino acid 
transporters (EAATs) expressed predominantly on astroglia. In astrocytes, Glu is converted to Gln by Gln 
synthetase and exported extracellularly to be taken up again by neurons. Additionally, system x-C is a 
cystine/glutamate antiporter expressed on glia that also contributes to Glu recycling. Glu receptors are present 
on presynaptic and postsynaptic neurons as well as on glial cells. These include both ionotropic receptors 
(NMDA, AMPA/KA) and metabotropic receptors (mGluRs). The effect of Glu is determined by the receptor 
subtype, localization (synaptic, perisynaptic and extrasynaptic), and interactions with various scaffolding and 
signaling proteins (not shown) in the postynaptic density. Glu receptor stimulation results not only in rapid 
ionotropic effects but also synaptic plasticity, e.g. long-term potentiation (LTP) and long-term depression (LTD), 
via cognate signal transduction cascades (Mark J. Niciu et al, 2012). 
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1.8.2.1 GLAST 
The glutamate transporters EAAT1 know also as GLAST, belong to the 
SLC1 family. Sodium-dependent glutamate transport is an electrogenic 
process [180], consisting of two distinct half-cycles: first, glutamate is co-
transported with three sodium ions and a proton and subsequently the 
binding sites reorient upon counter transport of potassium. Under 
physiological conditions, the inwardly directed sodium gradient and 
outwardly directed potassium gradient as well as the interior negative 
membrane potential promote the accumulation of the transmitter into the 
cell against its concentration gradient [181, 182], but at elevated external 
potassium concentrations the transporters mediate its efflux out of the cells. 
According to the transport cycle, elevated external potassium 
concentrations will render an increased proportion of transporters in the in 
ward facing conformation. In addition to the ion-coupled glutamate 
translocation, glutamate transporters mediate a thermodynamically 
uncoupled chloride flux activated by two of the molecules they transport, 
sodium and glutamate. Glutamate transporters have a non-conventional 
topology containing two re-entrant loops and two transmembrane domains 
(7 and 8) in their carboxyl terminal half [183]. Moreover, the two re-entrant 
loops are in close proximity. 
 
1.8.3 Glutamate signaling in glioma 
Mounting evidence suggesting that the glutamatergic system contributes to 
the pathophysiology of brain tumors is opening opportunities for the 
development of new models of pathogenesis, improved diagnostic tools 
and novel treatment strategies. A more complete understanding of 
glutamates' roles in the pathogenesis and pathophysiology of brain tumors 
may allow for an increasingly rational approach to drug development for 
these common, disabling illnesses. 
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Recent studies have implicated glutamate (Glu) signaling in the 
development and progression of malignant diseases. Glu, a non-essential 
amino acid, is the major excitatory neurotransmitter in the central and 
peripheral nervous systems. In addition, it functions as a source of energy 
for rapidly dividing cells such as lymphocytes and cancer cells [184]. 
Evidence is emerging for a role of Glu and its receptors in regulation of 
tumor growth. Several groups reported that glutamate receptor antagonists 
limit tumor growth Recent data show that blocking expression of selected 
GluR subunits inhibits proliferation of cancer cells in vitro [185, 186]. 
Glutamate neurotoxicity has been implicated in stroke, head trauma, 
multiple sclerosis, schizophrenia, ischemia and neurodegenerative 
diseases [187-190]. Three mechanisms seem to be responsible for Glu 
altered homeostasis control: a reduced reuptake of the neurotransmitter 
from the synaptic space,  an inverse activity of Glu receptor and a down-
regulation of these transporters expression. 
A dysfunction in Glu transport has also been reported in malignant gliomas 
[191]. The comparison of Glu transport into astrocytes versus their 
malignant counterparts showed an almost complete absence of Na+-
dependent Glu uptake into gliomas. 
The authors investigated glutamate uptake in glioma cells surgically 
isolated from glioma patients (GB) and in seven established human glioma 
cell lines, including STTG-1, D-54 MG, D-65 MG, U-373 MG, U-138 MG, U-
251 MG, and CH-235 MG. All glioma cells studied showed impaired 
glutamate uptake that of normal astrocytes. Furthermore, Western blots 
showed a loss of protein expression for EAAT2 and a mislocalization of 
EAAT1 to the nuclear Membrane [192]. Within 12 h, a monolayer of glioma 
cells maintained in a culture flask achieved concentrations exceeding 500 
µM [191]. This suggests that gliomas behaved exactly opposite to 
astrocytes, releasing Glu rather than sequestering it. Exposure of cultured 
hippocampal neurons to glioma-conditioned medium elicited sustained 
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[Ca2+] elevations that were followed by widespread neuronal death. 
Similarly, coculturing of hippocampal neurons and glioma cells, either with 
or without direct contact, resulted in neuronal death. These findings 
suggest that a deliberate release of Glu may promote tumor expansion 
through the release of excitotoxic concentrations of Glu [193] from the 
tumor as discussed further below. The initial studies that described the 
release of Glu and a loss of Glu homeostasis showed the assiduous 
release of glutamate from cultured human glioma cells but also 
demonstrated a complete loss of the Glt-1 and GLAST glutamate 
transporters in patient biopsy tissues. Follow-up studies demonstrate Glu 
release in tumor-bearing animals and glioma patients. To accomplish the 
former, Behrens et al. [194] implanted RG2 glioma cells into the cortex of 
Fisher rats and used microdialysis probes to sample and measure 
peritumoral Glu. They found that the peritumoral region showed fourfold 
elevated Glu compared with either the tumor or the remaining brain. A 
similar conclusion was drawn by Nedergaard and coworkers [195] who 
used a bioluminescence detection method to visualize Glu in living brain 
slices acutely isolated from tumor-bearing animals. This study went further 
and demonstrated that C6 glioma cells that lacked the ability to release Glu 
failed to grow solid tumors when implanted into rats. Together, these 
studies provided compelling evidence that gliomas release Glu in vitro, in 
situ, and in vivo. 
In neurons, the release of Glu occurs exclusively through synaptic vesicles 
and requires a Ca2+-dependent fusion event. Biophysical and 
pharmacological evidence suggests that Glu release from gliomas does not 
use these mechanisms but instead occurs predominantly via the system xc2 
cystine Glu exchanger [191]. This abundant amino acid carrier is Na+ 
independent and transports cystine into the cell in exchange for Glu being 
released. It requires both extracellular cystine and intracellular Glu to 
function. Elimination of Glu via multiple pathways is important for cell 
 
	  
64	  
survival, as discussed below, and can serve to provide alternate sources of 
energy for glycolysis-impaired cells and protection from free radicals. 
Elimination of Glu via multiple pathways is important for cell survival and 
can serve to provide alternate sources of energy for glycolysis-impaired 
cells and protection from free radicals. Another class of transporters, the 
excitatory amino acid transporters EAAT1-5 has been implicated in Glu 
release from neurons and glial cells at least under pathophysiological 
condition. Under conditions of energy failure, such as stroke, EAAT 
transporters can run backward exporting rather than importing Glu [196, 
197]. The released Glu has a multitude of targets all of which benefit the 
tumor yet compromise the patient [198]; malignancy degree of glioma 
appears to be related with the quantity of glutamate released and present in 
the tumoral microenvironment. An high and prolonged exposure at Glu 
leads to activation on numerous pathways which have an effect in 
enhancing tumor growth. A greater concentration of Glu at synaptic level 
increases the activation of NMDA and AMPA receptors on the neural 
membrane causing hyperexcitability which explains the frequent seizures, 
noticed in the 80% of patients with low-grade gliomas [199]. Both NMDA 
and AMPA receptor signaling are thought to be critical for activating a 
series of complex pathways responsible for maintaining synaptic strength 
and the encoding and ‘‘survival’’ of long-term memories. Conceptually, it is 
perhaps not surprising that tumors of glial origin manipulate Glu receptors 
to promote limitless proliferation and survival via the activation jof Glu 
receptors. 
AMPA receptors are highly expressed in glioblastoma and perform critical 
functions in glioma biology and enhance its malignant phenotype. They are 
heteromultimers composed of the GluR1–GluR4 subunits. glioblastoma 
appear to express low levels of the GluR2 subunit, which contributes to 
AMPA-R calcium permeability. Rzeski et al. demonstrated that antagonism 
of AMPA Glu receptors or the removal of calcium from the culture medium 
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in different tumor types including glioma decreased cell proliferation via 
both decreased cell division and increased cell death, suggesting that a 
common tumor proliferation mechanism involves Glu and Glu receptors 
[200]. Similarly, overexpression of AMPA-R promoted glioma proliferation in 
vitro, and reintroduction of GluR2 via adenoviral vector blocked this 
proliferation and induced apoptosis. Thus, glioma regulation of AMPA 
receptor subunit expression and calcium permeability may represent a 
novel mechanism for signal transduction pathway activation. Several 
mechanisms by which AMAP-Rs are able to modulate cell proliferation and 
survival have recently been described as AKT activation [201]. Additionally, 
it was recently demonstrated that AMPA-R stimulation promotes the highly 
oncogenic epidermal growth factor receptor EGFR or platelet-derived 
growth factor (PDGFR) expression  [202]. 
Elevate Glu concentration may be also responsible to glioma invasion 
capability. Interestingly, in gradient chambers, glioma cells migrated toward 
elevated Glu concentrations, suggesting that Glu could be considered a 
chemoattractant. [203]. Because glioma cells frequently show chain 
migration, particularly along blood vessels, the leading cell, through release 
of Glu, may stimulate trailing cells to follow. Recent studies have elucidated 
several mechanistic ideas as to how AMPA-R on glioma cells may regulate 
cell motility and tumor invasiveness. Overexpression of GluR1, the most 
abundant subunit of the AMPA-R in glioma cells, results in an increase in 
glioma adhesion to extracellular matrix (ECM) components such as 
collagen. AMPA-Rs appear to accumulate at focal adhesion sites where 
they may indirectly mediate interactions between the ECM and integrins. 
The enhanced adhesion to the ECM is mediated via increased surface 
expression of b1-integrin and subsequent activation of focal adhesion 
kinase (FAK). Overexpression of the GluR1 subunit of the AMPA-R in 
glioma cells activates FAK independent of AMPA-R activation. Although the 
mechanism through which GluR1 expression can promote FAK activation is 
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unknown, it may be related to FERM protein or integrin engagement. 
Stimulation of the AMPA-R with Glu or AMPA promotes cellular detachment 
mediated through Rac1 and causes an increase in transwell migration in 
vitro and an increase in tumor invasion in vivo [204]. 
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2. Aim of the study 
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Cancer immunotherapy strategies, aimed to re-educate the immune system 
to eradicate the tumor, met some recent success in prostate carcinoma and 
melanoma. However, the capacity of escaping the immune response, now 
considered one hallmark of cancer, limits the efficacy of immunotherapy. 
A number of studies have shown that in glioblastoma (GB) and other 
cancers a sub-population of cells, defined as cancer stem-like cells, 
express stem-programs and is responsible for tumor perpetuation. The 
reacquisition of stem cell features may be critical for tumor survival under 
environmental challenges. Thus, targeting GB stem-like cells (GSC) is one 
strategy to increase the potential efficacy of GB immunotherapy. 
The first aim of this study was to understand whether GLAST could be 
defined as a marker of GSC by investigating its involvement in 
tumorigenesis. GLAST positive cells were first isolated from murine GSC 
using an immunomagnetic sorting and compared with GLAST negative or 
unsorted GSC. In vivo experiments showed that GLAST-positive cells are 
more aggressive and lethal compared to GLAST-negative or unsorted cells. 
The observations obtained have allowed us to define GLAST as a potential 
marker of a more aggressive sub-population of GSC and moreover a 
specific therapeutic target. 
Accordingly with our preliminary observations, the second aim was to 
develop a strategy of immunotherapy based on the use of GLAST-derived 
peptides in a murine model of malignant glioma. In order to predict their 
immunogenicity, we identified four high scoring peptides using different 
computational algorithms. Synthesized peptides were emulsified in an 
adjuvant, Montanide™ ISA 51 VG, and administered subcutaneously in 
GL261 glioma-bearing mice. The effectiveness of peptides was evaluated 
in combination with granulocyte-macrophage colony-stimulating factor (GM-
CSF) used as an adjuvant. Activation of a specific anti-tumor immune 
response was investigated at different time points. Very important findings 
confirmed that immune activation, as a result of our vaccination protocol, is 
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related to a decrease of tumor invasiveness and lethality, with consequent 
significant increase of survival in treated mice.  
The last aim was to emphasize the translational relevance of GLAST as 
marker and glioma-associated antigen in human GB. By 
immunohistochemistry 32 GB specimens were analysed for GLAST 
expression. An high reactivity is significantly related to a decreased overall 
survival. In light of this observation and in terms of clinical research, GLAST 
expression in glioblastoma could constitute another important weapon by 
which GSC may proliferate and migrate.  
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3. Materials and Methods 
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3.1 Cells culture 
GL261 murine glioma stem cells (GSC) were maintained in DMEM-F12 
GlutamaxTM (Life Technologies), B-27 supplement 1X (Life Technologies), 
penicillin/streptomycin 1X, human recombinant epidermal growth factor 
(EGF; 20 ng/ml; Peprotech), and human recombinant fibroblast growth 
factor-2 (FGF-2; 20 ng/ml; Peprotech).  
The spleens and draining lymph nodes of immunized and control mice were 
surgically removed and mechanically processed in RPMI 1640 basal 
medium (LONZA) containing 5% fetal bovine serum, 20 mM HEPES, 2% L-
glutamine and penicillin/streptomycin.  
Erythrocytes were lysed with ice-cold ACK buffer (0.15 M NH4Cl, 1 mM 
KHCO3, 0.1 mM Na2 EDTA pH 7.4), and lymphocytes were resuspended in 
RPMI 1640 supplemented with 10% fetal bovine serum, 2% 
penicillin/streptomycin, 2% L-glutamine, 50 µM β-mercaptoethanol, 100 mM 
sodium pyruvate and 100x nonessential amino acids.  
We also added 10 U/ml of human recombinant IL-2 (Roche) to the medium 
for all in vitro experiments. 
 
3.2 Immunomagnetic sorting of GLAST positive cells 
To isolated GLAST positive cells, first 5-8 x 107 GL261-GSC were stained 
with the polyclonal anti-rabbit EAAT1 antibody (ab416 Abcam) in ice cold 
PBS + FCS 10% at the dilution of 1:200 for 30’ at room temperature. A 
secondary anti rabbit IGg-PE conjugated Antibody was used at the 
concentration of 1:200 in ice cold PBS + BSA 3% at the same condition. 
Subsequently, the cells were magnetically labelled with Anti-PE 
MicroBeads (Miltenyi Biotec) according to the manufacturer’s instruction. 
Then the cell suspension was isolated on a MACS Column system, which 
was placed in the magnetic field of a MACS Separator (Miltenyi Biotec). 
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Magnetically-labelled cells (GLAST positive) are retained in the column 
while the unlabeled cells (GLAST negative) run through. After removal of 
the column from the magnetic field, the magnetically retained cells can be 
eluted as the positively selected cell fraction. 
 
3.3 Glioma model 
In vivo experiments were performed using 6 old female C57BL/6N mice 
(Charles River Laboratory). 1 × 105 GL261-GSC are directly injected into 
the brain using a stereotactic frame. For tumor cells implantation the 
following stereotactic coordinates respect to the bregma were used: 0.7 
mm posterior, 3 mm left lateral, 3.5 mm deep into the nucleus caudatum. 
 
3.4 MRI studies 
Magnetic resonance imaging (MRI) was performed on a 7 Tesla Bruker 
BioSpec 70/30 USR Preclinical System at different days after tumor 
implantation.  
T2-weighted RARE sequence and T1-weighted spin echo sequences had 
been performed before and after intraperitoneal injection of contrast 
medium (Gadolinium DTPA). 
 
3.5 Peptide Prediction 
To determine whether GLAST peptide-based immunotherapy is protective 
against GL261 gliomas, we used the SYFPEITHI (http://www.syfpeithi.de/) 
and BIMAS (www.bimas.cit.nih.gov/molbio/hla_bind/) binding-motif 
algorithms to identify high-scoring target peptides containing both the 
murine major histocompatibility complex (MHC) H-2Db and the human 
HLA-A*0201.  
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We selected four peptides: Pep1 (44–52) YLFRNAFVL, score 23; Pep2 
(103–11) SLVTGMAAL, score 18; Pep3 (368–376) TLPITFKCL, score 16; 
and Pep4 (403–411) ALYEALAAI, score 15 (Tab. 1). The complete 
sequence of GLAST is available in the UniProt database 
(www.uniprot.org/). Lyophilized peptides were purchased from Primm 
(Primm S.r.l) and resuspended at a final concentration of 5 mg/ml/peptide 
using SEPICLEARTM 01 PPI (SEPPIC), a lipoamino acid compound 
designed to dissolve poorly soluble peptides. 
 
 
 
 
 
 
 
 
Tab. 1 Table of selected peptides. Peptides were predicted basing on computational algorithms. Peptides are 
restricted for both murine MHC H-2Db and human HLA-A*0201 and were synthesized from Primm S.r.l. 
 
 
3.6 In vivo experiment 
A total of 38 C57BL/6N mice (Charles River Laboratory), 19 immunized and 
19 controls (10 mice per group for survival studies and 9 mice per group for 
immunological and histological studies), were injected with 1 × 105 GL261 
cells/mouse into the nucleus caudatum using a stereotactic frame. The 
stereotactic coordinates with respect to the bregma were as follows: 0.7 
mm posterior, 3 mm left lateral and 3.5 mm deep into the nucleus 
caudatum. The immunized mice received subcutaneous (sc) injections of 
Peptide Sequences Rammensee 
Score
Pep1(44-52) YLFRNAFVL 23
Pep2(103-111) SLVTGMAAL 18
Pep3(368-376) TLPITFKCL 16
Pep4(403-411) ALYEALAAI 15
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all four peptides (15 µg/peptide) into different areas of the flank on days 4, 
11 and 18 after tumor implantation (day 0). The peptides were emulsified 
with MontanideTM ISA 51 VG (1:1) (SEPPIC) using two 2-ml sterile Luer 
Lock glass syringes (Artiglass S.r.l) and a three-way stopcock connector 
(MOVI S.p.A.) as recommended by the manufacturer. The immunized mice 
received a total of 3 µg of recombinant murine granulocyte macrophage 
colony-stimulating factor (GM-CSF) (Miltenyi Biotec) spread out over three 
injections into the same area of the peptide injections, beginning one day 
before the first vaccination. The control mice were treated with vehicle only 
(Montanide) on the same days as the immunized mice were vaccinated and 
injected with GM-CSF according to the experimental schema [Fig. 3A 
results]. 
 
3.7 Cytotoxicity assay 
Cytotoxicity assay. Lymphocytes from immunized and control mice were 
isolated on day 15 after tumor implantation. We tested their ability to 
recognize and lyse GL261 cells in vitro. A total of 2 × 106 splenocytes were 
pre-stimulated for 5 days in the presence of 5 × 105 3-Gy-irradiated naïve 
splenocytes as antigen presenting cells and 5 µg/mL of each peptide. The 
cells were cultured in 24-well tissue culture plates in a final volume of 2 
mL/well of complete RPMI 1640 supplemented with 10 U/mL IL-2. 
Splenocytes from healthy mice were irradiated (43855F Cabinet X-ray 
System, Faxitron® X-ray Corporation) and used as antigen presenting cells. 
Pre-stimulated lymphocytes were tested for GL261-specific cytotoxicity 
using different effector:target (E:T) ratios (10:1, 20:1 and 40:1). NIH 3T3 
cells were used as negative controls. To quantify cell lysis, a non-
radioactive cytotoxic assay (Cytotoxicity detection kit plus LDH, Roche) was 
performed according to the manufacturer’s instructions. Absorbances for 
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the various cell groups were used to calculate the percentage of specific 
cytotoxicity according to the following equation: (effector:target cell mix − 
effector cell control) − low control/(high control − low control) × 100, where 
the high and low controls correspond to the background target absorbance 
and the maximum target absorbance, respectively. 
 
3.8 Proliferation assay 
Immunized and control mice were sacrificed 15 days after tumor 
implantation, and a total of 2 × 106 splenocytes were primed for 5 days in 
the presence of 5 × 105 3 Gy-irradiated naïve splenocytes as antigen 
presenting cells, 5 µg/mL of all peptides and 10 U/ml of IL-2. After pre-
stimulation, 5 × 105 splenocytes were incubated for 24 h or 48 h in the 
presence of single peptides (5 µg/ml) and IL-2 and tested for their ability to 
proliferate. The number of viable cells was assessed using MTT Reagent 
(Millipore). The data are expressed as the percentage of proliferation, 
which is calculated according to the following equation: (OD stimulated 
splenocytes – OD splenocytes without peptide)/OD stimulated splenocytes 
× 100. 
 
3.9 Isolation of CNS-infiltrating lymphocytes 
CNS-infiltrating lymphocytes were isolated using a tumor dissociation kit 
(mouse, Miltenyi Biotec) on day 15 after tumor implantation. Briefly, glioma- 
bearing hemispheres (where GL261 cells were injected) from immunized 
and control mice (n = 4/group) were explanted, cut into small pieces of 2–4 
mm, and dissociated using GentleMACS (Miltenyi Biotec) according to 
manufacturer’s instruction. The cells were then suspended in PEB buffer 
(PBS/0.5% bovine serum albumin/ 2 mM EDTA) for labelling and flow 
cytometry evaluation. 
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3.10 Flow cytometry 
Lymphocytes from spleens, cervical draining lymph nodes and explanted 
gliomas of immunized and control mice were used for immune monitoring. 
Briefly, 1.5 × 106 cells were stained in PBS for 30 min at 4°C with the 
following antibodies: anti-CD4 PE-Cy5 (BD Bioscience), anti-CD3 FITC 
(Biolegend), anti-CD8-FITC (BD Bioscience), anti-CD8-PE (Biolegend), and 
anti-CD49d-APC (Miltenyi Biotec). For NK cell detection, an anti-NKp46-PE 
antibody (Miltenyi Biotec) was used according to the manufacturer’s 
instructions. For GLAST positive cells evaluation we used an Anti-GLAST 
(ACSA-1) PE (Miltenyi Biotec) Flow cytometry acquisition was performed 
on a MACSQuant instrument, and the data were analyzed with the 
MACSQuantify Software (Miltenyi Biotec). 
 
3.11 RNA extraction and Real-time PCR (RT-PCR) 
Total RNA was isolated from freshly harvested GL261 gliomas, 
lymphocytes and paraffin-embedded samples from immunized and control 
mice and used for gene expression analysis. Similar studies were also 
performed on cells from in vitro experiments. RNA was extracted with 
TRIzol reagent (Life Technologies) using the RNeasy MINI KIT (Qiagen) 
and the RNase-Free DNase Set (Qiagen). For paraffin-embedded samples, 
the Absolutely RNA FFPE kit (Stratagene) was used according to the 
manufacturer’s instructions. cDNA was synthesized from total RNA using 
oligo (dT) and M-MLV Reverse Transcriptase (Life Technologies). Specific 
primers for target genes were designed for Fast SYBR Green chemistry 
(Applied Biosystems) and purchased from Primm S.r.l. The relative mRNA 
levels were measured using a 7500 Real-Time PCR System (Applied 
Biosystems) and calculated using the ΔΔCt method. The expression levels 
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of the target genes were normalized to the expression level of β2-
microglobulin. The sequences of the primers are reported in the [Tab. 2]. 
 
Primers Sequence 5’- 3’ 
E4BP4 fw  5’-AAAACAACGAAGCTGCCAAA-3 
rev  5’-CCAAAACCAGGTCATTGAGG-3’ 
CD49d fw  5’-CAAACCAGACCTGCGAACA-3’ 
rev  5’- TGTCTTCCCACAAGGCTCTC-3’ 
CXCL10 fw  5’-GCTGCCGTCATTTTCTGC-3’ 
rev  5’-TCTCACTGGCCCGTCATC-3’ 
CCL5 fw  5’-CCCTCACCATCATCCTCACT-3’ 
rev  5’-GAGAGGTAGGCAAAGCAGCA-3’ 
CCL2 fw  5’-CATCCACGTGTTGGCTCA-3’ 
rev  5’-GATCATCTTGCTGGTGAATGAGT-3’ 
CCL4 w  5’-GCCCTCTCTCTCCTCTTGCT-3’ 
rev  5’-GAGGGTCAGAGCCCATTG-3’ 
CCL3 fw  5’-CAAGTCTTCTCAGCGCCATA-3’ 
rev  5’-GGAATCTTCCGGCTGTAGG-3’ 
NKG2D fw  5'-TGAAGTCACCTGTGTTTATGCAG-3' 
rev  5'-CACTGTCAAAGAGTCATCCAACA-3' 
GLAST (mouse) fw  5'-GATGCTGCAGATGCTGGTCTT-3' 
rev 5’-TATCTAGGGCCGCCATTACGT-3’ 
GLSAT (human) fw  5'-CGGACAAATTATTACAATCAGCA-3’ 
rev 5’-ATTCCAGCTGCCCCAATACT-3’ 
 
 
Tab 2. Sequence of primers designed for RT-PCR SybrGreen chemistry. 
 
3.12 Histology and immunohistochemistry 
Immunohistochemical analysis of GLAST (Santa Cruz), Ki67 (BD 
Bioscience), CD8 (R&D Systems), CD4 (R&D Systems), and CD11b (BD 
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Bioscience) was performed on paraffin-embedded sections. For double 
immunofluorescence, the tumor sections were incubated with anti-GLAST 
and anti-nestin antibodies overnight at 4°C and then incubated with Alexa 
Fluor 488-conjugated anti-rabbit secondary antibody. Quantitative analyses 
were performed on three to five independent fields per tumor by counting 
the number of cells in the photographed fields using the 40× objective of a 
Leica DM-LB microscope.  
 
3.13 Statistical analysis 
The differences between groups were analyzed using two-tailed Student’s 
t-tests and were considered statistically significant when p < 0.05. 
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4. Results 
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4.1 Results I: Characterization of the radial glia marker GLAST in 
a murine model of malignant glioma 
4.1.1 Enrichment of GLAST expressing cells in GL261 GSC increases 
tumour progression 
Our first evidence that glioma stem-like cells (GSC) can express GLAST 
came from a gene expression profile analysis performed on murine GL261 
cells that compared neurospheres (NS) and adherent cells (AC) [168]. To 
investigate the functional consequences of GLAST enrichment we isolated 
GLAST expressing GL261 GSC using the magnetic cell sorting technology. 
The positive fraction was 10- to 14-fold enriched for GLAST expressing 
cells [Fig. 1A]. When we injected unsorted, GLAST+ and GLAST- cells into 
mouse brain, we found that GLAST+ cells were significantly more 
aggressive than GLAST- cells or unsorted cells as confirmed by Kaplan 
Meier survival analysis [Fig. 1B].  
Brain magnetic resonance imaging (MRI) performed on a 7 Tesla Bruker 
BioSpec 70/30 USR Preclinical System at 22 days after tumor injection 
confirmed a different pattern of progression of GL261-derived gliomas from 
GLAST+ or GLAST- cells. Gliomas generated from GLAST- and unsorted 
cells were still confined to the homolateral hemisphere while tumors from 
GLAST+ cells appeared more aggressive and infiltrate the contralateral 
hemisphere [Fig. 1C]. 
We then explanted gliomas developed from unsorted, GLAST+, and 
GLAST- cells, and examined GLAST expression patterns using flow 
cytometry and morphological analysis [Fig. 2 A-B]. Gliomas from GLAST+ 
cells showed high GLAST expression whereas gliomas from GLAST- cells 
partially reacquired GLAST expression. The presence of many clusters 
from tumor mass in gliomas derived from GLAST+ cells is an evidence of 
their invasive capability. 
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Fig. 1 Enrichment of GLAST expressing cells in GL261 GSC increases tumour progression. A Flow 
cytometry histograms showed the percentage of enrichment and depletion after magnetic separation: unsorted 
GL261 population contains 4.7% GLAST positive cells, as determined by flow cytometry analysis. After 
immune separation the positive fraction was enriched about of 10 fold, expressing 47.7%; on the contrary the 
negative fraction was depleted completely containing only 0.3% of GLAST positive cells. B Kaplan Meier 
survival analysis confirmed that mice injected with GLAST+ GL261 cells had significantly lower survival rate 
than mice injected with unsorted or GLAST– cells (p=0.003 GLAST+ vs GLAST-; p=0.0006 GLAST+ vs 
unsorted; p=0.2 GLAST- vs unsorted) C T1 (right panel) with contrast medium and T2 (left panel, 20 slices; 
thickness 0.8 mm, no gap; TR: 2,658 ms/TE: 54 ms/RARE Factor 8/FOV: 2.20 9 2.20 cm2; averages 6; image 
matrix 256 9 256; in plane resolution 0.086 mm; acquisition time 8 min 30 s)  representative MRI images 
confirmed a different pattern of glioma formation. GLAST+ derived gliomas (Ci) are more infiltrative the 
surrounding parenchyma and the contralateral hemisphere than GLAST- (Cii) or unsorted (Ciii) derived 
tumors. 
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Fig. 2 GLAST expression is re-acquired in vivo. A Flow cytometry analysis on explanted gliomas showed a 
high GLAST expression in gliomas from GLAST+ cells. GLAST- glioma showed a partially reacquisition of 
GLAST expression. B H&E morphological analysis performed on paraffin embedded gliomas showed a 
relevant presence of cell clusters from the central tumor mass as an unique characteristic of gliomas derived 
from GLAST+ cells (left panel). Tumor from GLAST- cells (right panel) appeared very regular with a net border 
showing a slower progression. 
 
4.2 Results II: Immunotherapeutic approach with GLAST-derived 
peptides; activation of a specific anti-glioma immune response 
4.2.1 Vaccination with GLAST-peptides results in long-term survival 
and cytotoxicity 
The expression of GLAST in GL261-malignant gliomas and our preliminary 
results, in particular the evidence that GLAST enrichment impacts on 
progression and invasion of gliomas, support the idea that GLAST could be 
considered a good marker and target for GB immunotherapy. 
To determine whether GLAST peptide-based immunotherapy is protective 
against GL261 gliomas, C57BL/6 syngeneic mice were vaccinated three 
times with GLAST-derived peptides beginning four days after intracranial 
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injection of GL261 GSC [Fig. 3A]. Survival analysis demonstrated that 
GLAST peptides provide significant protection against GL261 GSC. All 
control animals (glioma-bearing mice treated with vehicle only) died by day 
25, whereas treatment with GLAST peptides emulsified with Montanide 
ISA-51 in combination with granulocyte macrophage colony-stimulating 
factor (GM-CSF) injections extended the survival of mice to 40% (p < 0.002 
vs. control) [Fig. 3B]. 
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Fig. 3 Vaccination with GLAST peptide results in long-term survival and induces specific antitumor 
cytotoxicity. A C57BL/6N mice were injected i.c. with GL261 GSC. Immunized mice received three s.c. 
vaccinations on days 4, 11 and 18 with all peptides (15 µg/single peptide) emulsified in MontanideTM ISA 51 
VG. A total of 3 µg of GM-CSF/mouse were administered during each treatment. Control mice were treated 
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with vehicle only. On days 15 and 22, three mice/group were sacrificed for immune monitoring and histological 
analysis. B Kaplan-Meier survival analysis showed that mice immunized with GLAST peptide (n = 10) survived 
significantly longer than control mice (vehicle, n = 10) (p < 0.002). C In vitro LDH cytotoxicity assay revealed 
that splenocytes from immunized mice recognize and lyse GL261 target cells but not NIH 3T3 cells. D Flow 
cytometry performed on splenocytes from immunized mice showed that the percentages of CD4+ and CD8+ T 
cells and NK cells were significantly increased when compared with controls (upper parts, CD4+ cells: 16.20 ± 
0.60% vs. 8.20 ± 1.30%, p = 0.01; CD8+ cells: 13.50 ± 2.10% vs. 4.10 ± 0.07%, p = 0.02; lower part, NKp46+ 
CD3- cells: 3.00 ± 0.30 vs. 0.90 ± 0.07, p = 0.009). Data were obtained from three different evaluations and are 
reported as the mean % ± SD of immunized vs. control mice. E RT-PCR analysis showed that the splenocytes 
of immunized mice express higher levels of IFNγ, TNFα and granzyme B. Infiltration of NK cells was 
investigated by analyzing the relative expression of the transcription factor E4BP4. **p < 0.001; ***p < 0.0001. 
 
To determine whether GL261-specific effector cells were generated in 
response to peptide vaccination, pre-stimulated splenocytes were assayed 
for in vitro cytotoxicity 15 d after tumor implantation. The splenocytes were 
re-stimulated with peptides and tested 5 days later for cytotoxic activity 
against GL261 GSC or NIH 3T3 cells as a negative control, using an LDH 
release assay. The splenocytes from mice treated with GLAST peptides 
displayed strong cytotoxic activity against GL261 GSC when compared with 
those from control mice [Fig. 3C]. The specificity of the cytotoxicity was 
confirmed by the total absence of reaction against NIH 3T3 cells. 
To characterize the direct effects of peptide vaccination in association with 
GM-CSF treatment on T-cell function, spleens and cervical draining lymph 
nodes were harvested 15 days after tumor implantation and multiple cell 
populations were quantified by flow cytometry. We observed significant 
increases in NK cells, CD8+ T cells and CD4+ T cells in the spleens [Fig. 
3D] and lymph nodes [Fig 4] of immunized mice when compared with 
controls. RT-PCR analysis of splenocytes revealed that GLAST peptide 
administration also enhanced the expression of interferonγ (IFNγ), tumor 
necrosis factor α (TNFα) granzyme B and the NK cell-specific transcription 
factor E4BP4 [Fig. 3E]. These data support the specificity of the vaccine-
induced effector response and the involvement of NK cells in the response 
to GLAST peptide immunization. 
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Fig. 4 GLAST-peptide administration activates systemic immune response. In cervical lymph nodes from 
immunized mice the percentage of CD4, CD8-T and NK cells increased significantly when compared to 
controls: A CD4+ 23.50 ± 2.10 vs. 15.20 ± 0.10, p =0.04; CD8+ cells 13.60 ± 1.40 vs. 5.10 ± 0.70, p = 0.01; B 
CD3- NKp46+ cells 2.00 ± 0.50 vs. 0.20 ± 0.07, p = 0.01 immunized vs. vehicle mice respectively. The panels 
show representative dot plots obtained from three different evaluations 15 days after tumor implantation. 
 
4.2.2 Immunization with peptides specifically targets GLAST positive 
glioma cells and modulates tumor microenvironment 
Fifteen days after tumor implantation, GLAST expression was significantly 
decreased in gliomas from immunized mice. Histological analysis showed 
that GLAST expression disappeared during the treatment course [Fig. 5A]. 
GLAST expression was 5.2 ± 2.1-fold lower in the tumors of immunized 
mice than in those of mice treated with vehicle only [Fig. 5B]. We also 
observed a significant reduction in Ki67-positive cells (p < 0.0001) in 
immunized vs. control mice [Fig. 5C]. Immunofluorescence analysis 
confirmed that GL261 gliomas from control mice strongly expressed 
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GLAST and co-expressed nestin on day 22, whereas GLAST and nestin 
expression were not detected in gliomas from immunized mice [Fig. 6]. 
 
Fig. 5 GLAST expression disappears in gliomas from immunized mice. A Histological analysis showed 
strong and diffuse positivity for GLAST in gliomas from vehicle mice. GLAST expression was decreased in 
gliomas from immunized mice (magnification 2.5× and 40×). B RT-PC R confirmed the significant decrease in 
GLAST expression in gliomas from immunized mice when compared with control mice (n = 3/group). ***p < 
0.0001. C Quantitative analysis of Ki67-positive cells summarized as the mean ± SD of the number of cells 
counted in 5 different 40× tumor sections. **p < 0.001. 
 
To characterize the effect of peptide vaccination on the tumor 
microenvironment, we investigated the expression of key molecules 
involved in immune activation (IFNγ and TNFα) or suppression 
(transforming growth factor, TGFβ1 and TGFβ2) by RT-PCR analysis of 
freshly harvested tumors from immunized and control mice (n = 3/group). 
IFNγ and TNFα expression levels were 9.60 ± 0.05- and 16.80 ± 0.03-fold 
higher (p < 0.0001), respectively, in immunized mice than in control mice. 
Moreover, the levels of granzyme B, the serine protease released by CTL, 
and E4BP4 were 25.60 ± 0.12- and 15.00 ± 0.05-fold higher (p < 0.0001 
and p < 0.01), respectively [Fig. 7A]. In contrast, TGFβ1 and TGFβ2 
expression levels were 3.4- and 2.6 ± 0.2-fold lower, respectively, in 
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immunized mice than in control animals (p < 0.001) [Fig. 7B]. Similar 
expression patterns were observed by RT-PCR analysis of paraffin-
embedded gliomas (data not shown). 
 
 
Fig. 6 Nestin/GLAST double positive cells disappear in gliomas from immunized mice. Gliomas 
from control mice treated with vehicle investigated 22 days after tumor implantation showed high levels of 
nestin (red) and GLAST (green) double positive cells (upper panel). In gliomas from mice immunized with 
GLAST peptides and sacrificed on day 22 double positive cells disappeared (lower panel). Three 
representative mice for each group have been investigated and representative images are displayed. 
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Fig. 7 Peptide immunization exerts immune modulation on tumor monicroenvironment. A Relative 
expression of IFNγ, TNFα, granzyme B, the transcription factor E4BP4 and B TGBβ1 and TGFβ2 were 
investigated using RT-PC R on RNA from immunized and control mice. **p < 0.001, ***p <0.0001, ****p 
<0.00001. 
 
4.2.3 Peptides immunogenicity and efficacy are related to granuloma 
formation 
To verify the immunogenicity of the GLAST-derived peptides, we first 
considered the appearance of potential local reactions during treatment. 
Only in immunized mice we observed the formation of a nodule at each 
injection site immediately after vaccination, enabling the slow, localized 
release of antigen. In immunized mice that displayed prolonged survival or 
specific immune reactions, we found four separate granulomas appearing 
as localized nodules with different sizes at the locations where each of the 
four peptides was administered. Non-necrotizing granulomas showing a 
high proliferation index and lymphocyte accumulation associated with 
macrophages were found at the injection sites of peptide 1 [Fig. 8A]. 
Granulomas that formed at the injection sites of peptides 2, 3 and 4 were 
characterized by the prevalence of macrophages, the total absence of 
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proliferating cells, CD8+ and CD4+ T cells, and noticeable central necrosis 
possibly caused by the activity of Th1 cells [Fig. 8B]. In particular, IFNγ is 
considered a major cause of necrosis in established granulomas as a 
consequence of exacerbated immune responses. 
 
Fig. 8 Local granulomas formation reflects peptide immunogenicity. A Granulomas derived from the 
injection site of peptide 1 appeared well developed and exhibited non-necrotic tissues. They were highly 
proliferative, as indicated by Ki67 staining and were infiltrated by CD4+, CD8+ and CD11b+ cells. B 
Granulomas from peptide 4 injection sites exhibited central necrosis, a total absence of Ki67-positive cells, 
CD8+ and CD4+ T lymphocytes and a massive CD11b+-cell infiltration. 
 
To test the in vitro immunogenicity of the four peptides used for 
vaccinations, splenocytes from control and immunized mice were primed in 
vitro using a mixture of irradiated antigen-presenting cells (APCs) and 
peptides. Five days later, the splenocytes were tested for their ability to 
proliferate in the presence of GLAST peptides. Lymphocytes from 
immunized mice proliferated significantly more than lymphocytes from 
vehicle receiving mice. The ability of peptides 2, 3 and 4 to induce robust 
proliferation correlated well with their in vivo immunogenicity [Fig. 9]. 
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Fig. 9 Proliferation test reveals the immunogenicity of GLAST-derived peptides in vitro. Splenocytes 
derived from immunized mice proliferated significantly more than splenocytes derived from vehicle mice. This 
was particularly evident in the presence of peptides 3 and 4 that appeared more immunogenic in vitro ***p < 
0.0001, ****p < 0.00001. 
 
4.2.4 The lack of autoimmune reactions and demyelination supports 
the safety of GLAST-peptide administration 
GLAST is not a glioma-specific antigen, and the risk of vaccinating with this 
antigen must be weighed carefully owing to the possibility of inducing 
autoimmune reactions targeting the CNS. To test whether the 
administration of GLAST-derived peptides might damage healthy areas of 
the CNS, we evaluated brain sections from immunized mice by hematoxylin 
and eosin (H&E) and Luxol Fast Blue (LFB) staining. We examined brain 
samples collected at different time points after immunization and observed 
that highly myelinated areas, such as the corpus callosum and the internal 
capsule, were densely stained with LFB, demonstrating that demyelination 
had not occurred in these mice. We also observed the integrity of the SVZ, 
where GLAST is expressed by radial glia-derived neural stem cells [Fig. 10 
A-B] and of the cerebellum (Bergmann glia). There was no evidence of 
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immune cell infiltration, and GLAST positivity was comparable in 
immunized and control mice [Fig. 10 C-D]. 
 
 
 
 
 
 
 
 
 
 
Fig. 10 Lack of autoimmune reactions and demyelination support the safety of GLAST-peptide 
immunization. A-B H&E and LFB staining of the subventricular zone revealed the total absence of 
demyelination in the brains of immunized (lower panel) when compared with healthy brains (upper panel). 
Highly myelinated areas appear densely stained with LFB (magnification 5× and 20×). C-D H&E staining of 
cerebellar tissue showed a structural integrity (magnification 5X) that was also confirmed by strongly positive 
GLAST staining at the level of Bergmann glial processes in immunized mice when compared with healthy mice 
(magnification 2.5X and 20X). Representative images from three mice are shown. 
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4.2.5 Increased local recruitment and tumor tropism of antigen-
specific T cells in immunized mice appears to be related to enhanced 
expression of chemoattractants 
The absence of autoimmune signs supports the idea that activated immune 
cells selectively travel to the tumor site. We isolated infiltrating lymphocytes 
from freshly harvested tissues (n = 4 for each group) and evaluated the 
percentage of CD4+ and CD8+ T cells within the CD3+ T cell population by 
flow cytometry. Representative plots show that CD4+ T and CD8+ T cell 
infiltration of tumor tissues was significantly increased in immunized mice (p 
< 0.001 and p = 0.01, respectively) [Fig. 11]. In addition, the percentage of 
CD8+ T cells expressing VLA-4 was higher in immunized than in control 
mice (p = 0.004), supporting the efficient CNS homing of CTL activated 
upon peptide vaccination. The frequency of NKp46+CD3- NK cells was 
very low in tumors from vehicle-treated mice and appeared to be slightly, 
but significantly, increased in tumors from immunized mice (p = 0.002). 
 
 
Fig. 11 Local immune infiltration increases in immunized mice. CNS-infiltrating CD4+ and CD8+ T cells 
and NK cells isolated from the glioma-bearing hemisphere on day 15 were more abundant in immunized mice 
than in control mice. The numbers reported in the dot plots represent the frequency of the investigated 
subpopulations.  
 
We next hypothesized that the attraction and recruitment of immune cells 
may be directed by the presence of chemoattractant factors. We thus 
examined the expression of CCL2 (which is involved in attracting 
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immunosuppressive regulatory T cells, Treg), CXCL10 (which is 
responsible for specific CTL recruitment), CCL3, CCL4 and CCL5 in 
immunized and control mice 15 d after tumor implantation. We performed 
RT-PCR and compared the results from the left hemisphere, where tumor 
cells were implanted, to those from the contralateral hemisphere and from 
tumor-free brain tissue. We found that CCL2 expression was 5.80 ± 0.10-
fold lower and CXCL10 expression was 11.70 ± 0.01-fold higher in 
immunized mice, compared with their control counterparts (p < 0.0001) 
[Fig. 12A]. Moreover, CCL3 and CCL4 expression was 2.20 ± 0.10- and 
2.00 ± 0.30-fold higher, respectively (p < 0.001). CCL5 was expressed at 
lower levels than the other chemokines in control mice and was increased 
significantly in immunized mice (15.00 ± 0.70-fold higher, p < 0.0001) [Fig. 
12B]. 
These data suggest that the CCL3/CCL4/CCL5 axis may play a role in the 
accumulation of immune cells (and particularly of NK cells) at the sites of 
tumor formation. To test this hypothesis, we investigated the expression of 
the NKG2D ligand (NKG2DL), and found that its was expressed at very low 
levels or was absent in control mice, while it was upregulated in immunized 
mice, suggesting that the GLAST peptide-induced anti-tumor immune 
response involves NKG2D-mediated NK cell recognition of tumor cells [Fig. 
12B]. In further support of the hypothesis that infiltrating and local cells 
cooperate to create a chemotactic gradient, we found that the expression 
levels of these chemokines were increased in immunized mice after a 
single injection of GLAST peptides (data not shown). 
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Fig. 12 Tumor microenvironment shows increased levels of chemoattractant factors. A CCL2 expression 
was measurable in vehicle control mice and decreased significantly in immunized mice. On the contrary 
CXCL10 and CXCL3 expression level was higher in immunized mice when compared with control mice. B 
CCL4, CCL5 and NKG2DL were expressed at higher levels in immunized than in control mice. mRNA levels 
from the hemisphere where the tumor cells were implanted and from the contralateral hemisphere were 
normalized to the relative quantity of β2-microglobulin. The relative expression of chemokines was compared 
with that detected in normal brain tissue. 
 
4.3 Results III: Definition of GLAST as a clinical marker 
In order to emphasize the translational relevance of GLAST as marker and 
glioma-associated antigen we will extend our studies to human GB.  
Through immunohistochemistry we examined a series of 50 human GB 
specimens; we found strong GLAST expression in the large majority of 
samples, specifically located on the plasma membrane of the tumour cells 
[Fig. 13]. To validate the relevance of GLAST expression in GB, we 
selected a group of patients (n=36) who were treated with surgery, 
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radiotherapy, and temozolomide [1], and we correlated their GLAST 
expression with overall survival (OS). We found that a high percentage of 
GLAST+ cells and a strong or moderate reactivity correlated with a lower 
overall survival of patients (p= 0.02), supporting a potential role of GLAST 
as a clinical marker in the prognosis of GB patients [Fig. 14]. 
 
 
Fig. 13 Glioblastoma specimens show strong GLAST reactivity. GLAST expression was investigated in 50 
paraffin-embedded human GB specimens. GLAST is preferentially localized in the plasma membrane of 
tumour cells; a high percentage of GLAST+ cells was detected in the majority of samples analysed. 
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Fig. 14 GLAST expression correlates with OS of GB patients. GLAST expression was investigated by 
immunohistochemistry and compared with the OS in a cohort of 36 GB patients that received standard cure 
with radio- chemotherapy. A-B Patients with negative-low expression of GLAST survived significantly longer 
than patients with a moderate-high percentage of GLAST+ cells (p=0.028). 
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5. Discussion 
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Many clinical trials involving the immune system are now ongoing in several 
types of cancer including glioblastoma (GB). They are based on the 
rationale that tumor associated antigens (TAA), preferentially expressed by 
tumor cells, are recognized by effectors immune cells.  
There are four important issues to consider in designing an effective cancer 
vaccine: identify potent tumor rejection antigens; stimulate an effective anti-
tumor immune response; avoid autoimmune pathologies; and prevent the 
immune escape. The identification of GB cell subpopulations, expressing 
stem programs, provides the background for immunological studies aimed 
at their targeting. Murine and human GB contain a fraction of cells with 
stem cell-like features (GSC) and it has been proposed that only this 
population may be responsible for glioma recurrence. It was found by 
several groups, including our, that GB populations enriched with GSC can 
give rise to gliomas resembling closely the original tumor and rather 
different from the experimental gliomas generated by brain injection of 
established cell lines [48, 205]. These glioma stem-like cells have been 
found to preserve genetic alterations of their originating tumor and are 
tumorigenic in nude mice [206, 207]. We have found that GSC can be also 
obtained by established cultures from murine gliomas, like GL261. GL261-
GSC have similar features to human GSC, as we extensively demonstrated 
in 2006. Dendritic cells (DC) loaded with GL261-GSC were significantly 
more effective than DC loaded with serum-cultured GL261 at inducing an 
immune rejection of highly malignant gliomas that were otherwise lethal in 
about one month. With these experiments, we provided a proof of principle 
that the use of a cellular population enriched in GSC for DC loading may 
increase the efficacy of anti-glioma (and possibly anti-tumor) 
immunotherapy [168]. 
Some studies have investigated the relationship between the GSC and the 
immune system. The results underscore for example the relevance of the 
GSC in the immuno-escape mechanism [208-211]. The relationship 
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between the immune system and cancer is dynamic and complex. 
Individual human tumors harbor a multitude of somatic gene mutations and 
epigenetically dysregulated genes, the products of which are potentially 
recognized as foreign antigen [64, 210]. However, the overriding 
relationship between the immune system and growing cancer is one of 
tolerance, in which, paradoxically, foreign molecules expressed by tumor 
cells are viewed as self. Growing cancers contain tumor-infiltrating 
lymphocytes (TILs), which are ineffective at tumor elimination in vivo but 
can exert specific functions (eg, proliferation, cytokine secretion, cytolysis) 
outside the immunosuppressive and tolerogenic tumor microenvironment. 
This is because the tumor milieu contains suppressive elements including 
regulatory T cells [110] and myeloid-derived suppressor cells (MDSC) 
[213]; soluble factors such as interleukin 6 (IL-6), IL-10, vascular 
endothelial growth factor (VEGF), and transforming growth factor beta 
(TGFβ) [75]. 
Important observations regarding the ability of NK cells and CD8 + T cells 
to recognize and destroy GSC are published [214-216] and cancer 
immunotherapy has become an interesting therapeutic option in several 
type of cancers. 
The identification of a specific marker associated to cancer stem-like cells 
is mandatory, however this urgency conflicts with the evidence that 
strategies directed against one antigen only may have limited efficacy. Two 
aspects are important for appropriate therapeutic design: to overcome 
tolerance in order to elicit specific anti-tumor response and to avoid 
undesired autoimmune side effects. 
In characterizing expression profiles of GL261-GSC we have found that 
expression of a group of five genes, including GLAST, is significantly up-
regulated [168]. All these genes are expressed by radial glia. Interestingly, 
Buylla et al showed that radial glia is a potential source of adult neural stem 
cells [217]. To better define and characterize GSC we needed a surface 
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marker that would enable isolation; we have addressed the possibility to 
isolate GSC using GLAST as a marker.  
GLAST, an astrocyte specific glutamate/aspartate transporter, is involved in 
the glutamate uptake in the CNS, and it is required for normal 
neurotransmission. Glutamate release by several membrane transporters 
promotes growth of malignant glioma and it appeared involved in invasion 
and angiogenesis [169, 203]. Glutamate-secreting gliomas promote an 
inflammatory response within the surrounding tissue, possibly induced by 
the neural death or by glutamate itself. The high expression of GLAST on 
the GSC plasma membrane supports the idea that it may be a good target 
for an immunotherapeutic approach. Furthermore, results obtained in the 
GL261-GSC model suggest an involvement of GLAST in conferring a more 
aggressive phenotype. 
In the first part of this project we wanted to understand whether GLAST 
could be defined as a marker of GSC by investigating his involvement in 
tumorigenesis.  GLAST positive cells were first isolated from murine GL261 
using an immunomagnetic sorting and compared with GLAST negative 
sub-population or unsorted cells. In vivo experiments showed that GLAST 
positive cells are more aggressive and lethal compared to the GLAST 
negative sub-population. In vivo monitoring performed by MRI at different 
time points after GL261 implantation have confirmed the hypothesis that 
GL261 GLAST positive-derived tumors are more aggressive compared with 
GLAST negative-derived tumors, causing a more extended lesion due to 
the migration of cells through the ventricles to the contralateral hemisphere. 
These preliminary observations have allowed us to define GLAST as a 
potential marker of a more aggressive sub-population of GSC and 
moreover a specific therapeutic target.  
In several published studies expression of aberrant protein in cancer cells 
was used to develop vaccines: HER-2 for example has been used as a 
target in breast and ovarian cancer [218], MUC-1 and WT-1 in several 
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types of cancer, including lung, stomach and in some haematological 
cancers [219], EGFRvIII has been reported as a suitable target in GB [152] 
but until now GLAST has not previously been reported to be expressed in 
GSC.  
In term of preclinical studies, we provided an immunotherapeutic approach 
with four GLAST-derived peptides. In our study, GLAST-derived peptides 
were emulsified with the adjuvant Montanide™ ISA 51 VG and 
administered in conjunction with GM-CSF were effective in prolonging 
survival, enhancing systemic and local immunity, and modifying the tumor 
microenvironment.  
Loss of GLAST expression in gliomas from immunized mice provided 
evidence of the induction of a specific antitumor immune response against 
GLAST-expressing tumor cells that resulted in subsequent immunoediting 
and tumor escape [156, 220]. A recent example of immunoediting was 
provided by studies involving immunotherapy targeting the tumor-specific 
EGFRvIII mutation, which is highly expressed in GB [155]. 
In spite of immunoediting, however, we found that targeting the radial glia 
marker GLAST significantly increased the survival of mice bearing GL261 
gliomas. We also observed a remarkable modulation of the glioma 
microenvironment and an increase in peripheral NK cells in immunized 
mice. In addition, the NK cell-specific transcription factor E4BP4 [221] was 
expressed at higher levels in gliomas from immunized mice than in those 
from control mice, confirming the contribution of NK cells to the antitumor 
response.  
NK-cell infiltration led to increased IFNγ expression, and its local 
accumulation exacerbated CXCL10 production in the glioma 
microenvironment. CXCL10, in turn, was responsible for the recruitment of 
antigen-specific CTL, defined as Tc1, to GL261 gliomas. The production of 
IFNγ and the expression of VLA-4 by antigen-specific Tc1 cells were found 
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to be critical for efficient infiltration into the glioma mass [222]. 
NK cells are able to recognize the loss of MHC I molecule, an important 
event in tumor immunoediting. Recent studies also show the potential of an 
NK-cell response in fighting GSC.  In agreement with these findings, we 
detected upregulation of NKG2DL expression in gliomas from immunized 
mice. NKG2DL is weakly expressed or absent in GSC [223], and TGFβ 
seems to be responsible for both this decreased expression of NKG2DL 
[224, 225] and the downregulation of NKG2D receptor on NK cells [226]. 
Thus, the down-regulation of TGFβ observed in mice immunized with 
GLAST peptides could influence NKG2DL expression and reverse the 
suppression of NK cells. The efficacy of our therapeutic strategy could be 
hampered by immune tolerance, as GLAST is expressed by the normal 
CNS tissue; conversely, the absence of tolerance could result in 
autoimmune reactions. Our data suggest that the absence of toxicity 
following GLAST-derived peptide immunization may be attributed to the 
recruitment of activated immune cells to the tumor site by a chemotactic 
gradient. In particular, gliomas in GLAST peptide-treated mice displayed 
upregulation of CXCL10 concomitant with downregulation of CCL2, an 
important chemokine involved in Treg migration [106]. Furthermore, we 
found that CCL5 was highly expressed in gliomas of immunized mice.  
This chemokine may play a dual role depending on its source. 
CCL5/RANTES (regulated upon activation, expressed and secreted by 
normal T cells) inuces chemotaxis in T cells, monocytes, dendritic cells, NK 
cells, eosinophils and basophils [227-229]. When produced by CD8+ T 
cells, CCL5 is associated with effector functions, together with CCL3 and 
CCL4 [230-232], and antigen-specific T cells are activated in response to 
CCL5 [233]. In contrast, tumor secreted CCL5 is deleterious and acts as an 
immunosuppressor, and its inhibition improves the efficacy of 
immunochemotherapy [234].  GL261 gliomas treated with vehicle express 
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low levels of CCL5, whereas gliomas from mice immunized with GLAST 
peptides express much higher levels of CCL5. These findings support the 
idea that, in our experimental system, CCL5 expression is related to the 
presence of infiltrating immune cells. 
In conclusion, both NK cells and CD8+ T cells can play an important role in 
tumor rejection: NK cells may be one important source of IFNγ a crucial 
cytokine that mediates CD8+ T-cell activation [235]; our protocol of 
immunotherapy with  GLAST-derived peptide  delayed and, at least in 
some cases, abolished tumor growth, resulting in the survival of 40% of the 
immunized mice. Recent studies suggest that some chemotherapeutic 
agents possess immune stimulatory effects [236, 237]. We thus plan to 
design immunochemotherapy combinations in an attempt to potentiate the 
specific antitumor immunity achieved following GLAST peptide 
immunization. In addition, a more complete appraisal of the safety of 
GLAST immunotherapy is essential to assess the translational potential of 
these findings.  
The main result of this study is the definition of GLAST as an attractive 
glioma-associated antigen for targeting in peptide-based immunotherapy in 
GB patients. To understand if GLAST could also represent a good 
predictive marker in association with the overall survival of patients with GB 
we examined a series of GB specimens by immunohistochemistry. We 
found that a high percentage of GLAST+ cells and a strong or moderate 
reactivity correlated with a lower overall survival of patients. Several 
published work described the pathophysiology of GLAST signalling and 
help us to understand our observation. In fact, as previously mentioned, 
GLAST has a physiological role in the glutamate uptake after 
neurotransmission; extracellular concentration of glutamate is maintained 
very low which preventing neurotoxicity and CNS damage [195]. However, 
in several pathological conditions such as ischemia, hypoxia, and 
neurodegenerative disorders, astrocytes can reverse glutamate uptake 
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acquiring a skills release of the neurotransmitter [188]. Cells from glioma 
have been shown to have the same altered activity: the uptake of glutamate 
appears to be reduced and its elevated extracellular concentrations 
suggest a strong release [211]. In a study of Ye and colleagues, glutamate 
transporters were characterized in several human glioblastoma cells. They 
found an over- expression of the cystine-glutamate transporter, a reduction 
or a complete absence of the Glt-1 transporter, and a translocation of 
GLAST in the nuclear membrane [192]. These differences and the 
abnormal activity of glutamate transporters on the tumor cells are the major 
causes of the extracellular glutamate accumulation. In vivo, the release of 
glutamate in the tumor microenvironment was confirmed both in glioma 
models [195] and in humans [238]. Malignancy rate appears to be related 
to the amount of glutamate released and its presence in the tumor 
microenvironment [195]. The high extracellular glutamate levels may have 
two important consequences: to act as a growth factor for tumor cells 
themselves, to induce apoptosis of parenchyma cell [203] Infact, the higher 
concentration of glutamate at the synaptic level increases the activation of 
NMDA and AMPA receptors causing neuronal hyperexcitability resulting in 
a Ca2+-dependent neurotoxicity. The increase in intracellular Ca2+ induces a 
mitochondrial dysfunction and the activation of different lipase, protease, 
phosphatase and nuclease that induce apoptotic pathway. 
The evaluation of important roles of GLAST in aberrant glutamate release 
could support its relevance in the biology of glioblastoma. In our murine 
model, the association of immunotherapy and chemotherapy may represent 
an attractive approach to modulate chemokine expression in tumor 
microenvironment, reinforcing the recruitment of additional effector cells 
and enhancing the therapeutic efficacy of vaccinations. 
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6. Future Perspectives 
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Development of therapeutic vaccines has been the subject of several 
phase I or phase II studies especially based on the use of DC loaded with 
glioma-derived tumor antigens. These studies provided data on safety and 
efficacy in clinical trials using autologous tumor lysate-loaded DC [137, 138, 
240].  
At the Fondazione I.R.C.C.S. Istituto Neurologico “Carlo Besta” our 
experience with DC immunotherapy started in 2006 in close collaboration 
with the Cell Factory located within our Institute. Six patients suffering from 
GB were treated in 2006-08 on a compassionate basis, whereas in 2010 
and 2011 respectively, two phase I studies called DENDR2 (EudraCT 
2008-005038-62) and DENDR1 (EudraCT 2008-005035-15), coordinated 
by Dr. Finocchiaro, were approved by the Ministry of Health and started. In 
both studies we are testing the effects of immunotherapy with DC loaded 
with tumor lysate in conjunction with chemotherapy (CT) with TMZ in 
patients with first diagnosis (DENDR1) and recurrence (DENDR2) of GB. 
The therapeutic program of DENDR1 includes radical surgical resection of 
the tumor, followed by radiotherapy (RT) and concomitant adjuvant CT with 
TMZ according to the Stupp protocol [1]. Immunotherapy follows 
concomitant RT/CT, and it includes seven injections of tumor lysate-loaded 
DC overall.  
The therapeutic program of DENDR2 for recurrent GB patients includes 
surgical resection of the tumor, followed by immunotherapy with 5 injections 
of tumor lysate-loaded DC and simultaneous treatment with TMZ.  RT and 
TMZ chemotherapy are not performed on these patients because they have 
already experienced this treatment before and they have presented 
recurrence despite that. 
Nevertheless, it is already clear that the definition of novel targets and the 
modification of immune suppression at the tumor site are important points 
to be addressed if DC immunotherapy has to added to the list of standard 
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treatments available for GB. At the same time the existence of cancer stem 
cells requires deeper studies to be accepted and understood.  
As a preclinical data, we have first demonstrated in the GL261 model that 
DC targeting GB cancer stem cells (GSC) are particularly effective in 
eliciting anti-tumor responses [168]. A patent has been derived from this 
study (US2010071081 -A1-; www.epo.org). 
In preliminary experiments in the GL261 model of malignant glioma we 
have found that mice vaccinated with DC loaded with GSC lysate survive 
longer than others vaccinated with tumor lysate (unpublished data).  In our 
laboratories we isolate and culture GSC from fresh GB specimens growing 
in the absence of serum and in the presence of EGF and bFGF as 
neurospheres after mechanical and enzymatic dissociation. We appreciate 
that NS may mirror much more closely than previous, serum-based glioma 
cell lines, the actual biology of GB [241, 242]. These GSC have been used 
as an in vitro model in many of our published studies [28, 169, 243, 244]. 
Recently, in our Institution the Cavitation Ultrasonics Surgical Aspirator 
(CUSA) is preferably used for GB surgery.  CUSA facilitates the removal of 
large tumors from inside out and delivers an irrigating solution that converts 
the fragmented tissue into an emulsion and then aspirates the particles 
directly into a sterile bag.  
The bag contains some larger pieces of tissue, debris and high amounts of 
erythrocytes, and occasionally necrotic or reactive tissue. Tissue fragments 
in CUSA bags after several rounds of spinning ad washing are dissociated 
using the GentleMacs Dissociator (Miltenyi Biotec) that provides a closed 
system and reproducible results. We have optimized a gentle and effective 
protocol starting from appropriate gentleMACS programs, which allows 
obtaining a high yield of viable tumor cells. After processing cell 
suspensions are cultured as neurospheres in DMEM/F12, B27 supplement, 
human recombinant b-FGF and EGF.  
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During the last year we obtained from the Department of Neurosurgery of 
Istituto Besta a total of 41 CUSA. GB were the most represented brain 
tumors (78%). Using tumor fragments obtained from surgery and combining 
a mechanical dissociation with enzymatic disaggregation on a series of 
primary GB we previously obtained GSC in 52% of the cases. This 
percentage is now increased to 70% with the use of surgical material in 
CUSA and the optimized processing.  This improvement and the use of a 
closed system providing a wider margin of safety encouraged us to 
incorporate this process in a clinical trial protocol which plans to use GSC 
as a source of antigens for DC replacing the whole lysate from GB 
specimens used in current immunotherapy protocols presently active at 
Istituto Besta. Another contribution for our study would be related to the 
identification of GSC markers and their investigation as a clinical marker in 
association with the prognosis of brain tumor patients. 
The identification of five genes related to the radial glia signature, including 
GLAST (Glutamate Aspartate transporter) stems from our studies on 
expression profiles of murine GL261 GSC and confirmed in human GB 
GSC [168]. GLAST has been selected as a GSC marker and its enrichment 
impacts on tumor aggressiveness and progression, constituting a 
background for translational relevance 
In our study we showed that immunization with GLAST peptides efficiently 
promotes specific anti-tumor response in the murine glioma GL261, 
preventing the tumor progression only in 40% of immunized mice. In term 
of preclinical studies, we hypothesize that chemo-immunotherapy 
combination using GLAST peptides may convert the glioma 
microenvironment, especially through chemokine expression, into a site 
permissive for an efficient immune response and also act as an adjuvant 
able to instigate and sustain both systemic and local tumor response 
[Fig.1]. 
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Fig. 1 Cytotoxic T lymphocytes produce IFNγ after peptide-loaded DC stimulation. CD3+CD8+ were 
gated and evaluated for the IFN-γ production by flow cytometry. Peptide 3 and 4 induced a significant response 
compared to peptide 1 and 2 (not shown) that failed to stimulate T cells. 
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